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ABSTRACT
C-reactive protein (CRP) is a serum protein that binds to damaged membranes
and initiates the complement immune response. Different forms of CRP are thought to
alter how the body responds to inflammation and the degradation of foreign material.
Despite knowing that a modified form of CRP(mCRP) binds to downstream protein
binding partners better than the native pentameric form, the role of CRP conformation on
lipid binding is yet unknown. In this work, three main assays were performed to
characterize how conformation affects CRP-membrane interactions. The first assay
utilized supported lipid bilayers that mimic the plasma membrane of apoptotic cells. The
results show that CRP interactions vary with protein conformation, lipid composition,
and membrane shape and that the mechanism by which CRP recognizes damaged
membranes depends on the combination of all three. The second assay focused on CRP
interactions with cellular membranes by using induced apoptosis in MES-SA cells to
characterize how CRP recognizes damaged cellular membrane. Monitoring the
disassociation of pCRP to mCRP on apoptotic cell membrane with a fluorescent RNA
aptamer that specifically binds mCRP but not pCRP allowed for quantitative analysis.
Thirdly, a fluorescence quenching assay was utilized to characterize CRP conformational
states using 8-anilino-1-naphthalenesulfonic acid (ANS), a fluorescence probe that binds
to the hydrophobic regions of a protein. The unfolding of CRP using different denaturants
was assessed using tryptophan fluorescence assay. Urea-EDTA, Guanidine-HCl, and
ii

SDS with heat were used to perturb the pentameric state. All treatments give rise to a
monomeric state in native PAGE experiments. As revealed by ANS fluorescence,
treatment with 2.5M GndHCl, 3 or 6 M urea, or 0.01% SDS caused hydrophobic portions
of CRP to be exposed. Based on this data, we conclude that the two forms of CRP studied
here have different mechanisms of action.
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CHAPTER ONE: INTRODUCTION
1.1 C- Reactive Protein (CRP)
Cardiovascular diseases (CVD) are one of the leading causes of death in the
world. Annually about 16.7 million deaths are attributed to chronic inflammatory
diseases of the arteries and atherosclerosis[1]. In the United States around 610,000 cases
of myocardial infarction every year are attributed to atherosclerosis[1]. The mortality
rates of CVD have been reduced by 33% in the last 20 years due to improvements in
treatment and early prevention. However, the elevated rate of current incidence requires
researchers to develop treatments that prevent CVD[1]. Clinically, C-reactive protein
(CRP) is a good indicator and a risk factor for CVD[2], [3]. CRP has been shown to
accumulate at sites of inflammation[2], [3] and an elevated level of CRP is linked to
chronic inflammation and cardiovascular disease (CVD)[3]. CRP was discovered by
Tillet and Francis over 80 years ago and initially named C-reactive substance due to its
reactivity and ability to precipitate the C- polysaccharide of the pneumococcus cell
wall[4]. The blood plasma level of CRP rises dramatically in response to infection, tissue
injury, and inflammation. CRP is a plasma soluble protein and acts as a marker for the
cardiovascular disease (CVD)[3]. CRP levels in serum increase significantly and rapidly
to 1,000 fold during the first 24-48 hours in response to inflammation. In 2003, studies
demonstrated that people with slightly elevated levels of CRP, in a range between 3 and
10 µg/mL, are at risk for developing CVD, leading to CRP being used as a biomarker for
1

CVD[5]. This view was later revised when CRP was considered a participant and
mediator in the formation of lesions and atherosclerosis due to its inhibitory effect of
nitric oxide production by endothelial cells. Quenching the releasing of NO leads to the
stimulation of endothelial cell apoptosis and inhibition of angiogenesis[5]. Studying CRP,
a mediator and participant in CVD, will lead to a better understanding of the mechanism
of plaque formation in heart disease.
CRP is a pentameric protein belonging to the pentraxin family, and is composed
of five identical subunits (protomers) associated noncovalentaly[6]. The crystal structure
of CRP was solved in 1999 and is shown in Figure 1. The crystallographic data shows
that each promoter has binding sites for two calcium ions and one binding site for
phosphatidylcholine (PC) on the recognition face of CRP (face B). The major interaction
between PC containing ligands and CRP bound calcium ions occurs via a phosphate
oxygen group of PC. The opposite face (Face A) exhibits binding sites for C1q, Fc
receptor (FcR)[7], integrins[8] and C4b- binding protein[9].
CRP exists in at least two different conformations with distinct bioactivities.
Native pentameric CRP (pCRP) and modified CRP (mCRP) are the most well studied
forms. Previous work by Potempa in 1983 suggests that human CRP has two distinct
forms, one is a native CRP (110 kDa) bound to PC, and the other as free subunits (22.5
kDa), which expresses a new epitope leading to different reactivity. mCRP binds to
downstream binding partners, such as factor H, C1q and C4bp[10]. Five novel molecular
forms of CRP in human plasma which are different from pCRP and mCRP have also
identified recently with one form significantly linked to obesity.
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Figure 1. CRP crystal structure.
CRP is a pentameric protein binds one phosphocholine head group (grey/red structure in
center of monomer) per monomer unit in a calcium dependent manner (Ca2+ is green,
two per monomer). Image was taken from the protein data bank (PDB Identifier: 1B09),
and the structure was solved by Devaraj, et.al.[11].

The main functions of CRP are to control inflammation, stimulate the clearance of
tissue components and damaged cells, and to recruit damaged cells for phagocytosis[4].
In 1981, research showed for the first time that CRP has a protective activity against
3

Streptococcus pneumonia infection in mice[12]. CRP is involved in the activation of the
classical complement pathway through its binding to different ligands which leads to the
killing of microorganisms and the protection of the host. Among the ligands that mCRP
is able to bind to activate the classical complement cascade, C1q binding is one of the
most significant functions of CRP. mCRP binds C1q, which activates the complement
response, and also C4bp1 and factor H, both of which attenuate the immune response.
The monomeric form of CRP leads to pro-inflammatory states by binding to integrin
proteins on monocytic U937 cells[8].
By binding C1q as part of the classical complement pathway, CRP is involved
with both the innate and adaptive immune system. CRP activates the classical
complement cascade and promotes an anti-inflammatory response when it binds to an
apoptotic cell surface, by increasing binding of C3b/bi and C1q[4]. CRP binding
improves the phagocytosis of apoptotic cells by macrophages. CRP inhibits the
alternative complement pathway by recruiting factor H to the cell surface which inhibits
C5 convertase and prevents the formation of the membrane attack protein (MAC).
Another important property of CRP is its binding to Fcγ receptors which leads to
increasing phagocytosis and releasing of inflammatory cytokines[4].
Phosphatidylcholine (PC) is the most well described small molecule that CRP
recognizes and binds to on the surface of damaged and apoptotic cells[2], [13]. The Kd for
CRP-phosphorylcholine ineraction is 18µM[14]. It is not clear why CRP does not bind
PC present on healthy cells. Past work has shown that lysophosphatidylcholine (lysoPC)
and PC are recognized by CRP. Both of these lipid are common in damaged membranes,
like apoptotic cells, but lysoPC is less common in healthy cells. It naturally occurs as a
4

result of partial hydrolysis of phosphocholine by the enzymatic action of phospholipase
and represents ≤ 3.0% of the phospholipids in a cellular membrane[15]. It has also been
shown that certain phospholipases or membrane damage cause PC to become more
exposed and accessible to CRP [4]. Others have shown that the incorporation of lysoPC
in the natural lipid bilayer induces positive curvature[16], by causing a disturbance due to
acyl chain mismatch[17], and promotes CRP binding in phosphatidylcholine vesicles[18].
Also, lysoPC has been shown to mediate the binding and dissociation of pCRP on the
surface of Jurkat T cells[19].
In addition to lysoPC, CRP shows binding activity to both oxidized LDL
(OxLDL) and apoptotic cells by recognition of their phosphorylcholine moiety that
becomes more exposed due to oxidation which leads to opsonizing them for
macrophages.[13] Lipid oxidation leads to a conformational switch in the structure of
phospholipids by making the fatty acid tail hydrophilic. This causes protrusion of
oxidized fatty acids from hydrophobic moiety to an aqueous environment[20].
Beyond phosphatidylcholine oxidation, membrane curvature has been shown to
enhance the binding of CRP to damaged membranes[21]. CRP shows curvature
dependent binding to lipoprotein particle mimics (LPP) with high binding to LPP with
diameter ≤ 28 nm. This binding causes CRP to disassociate to mCRP which expose a new
epitope for C1q binding[21]. We hypothesize that both lipid composition and membrane
curvature are factors by which CRP forms recognize damaged membranes for clearance.
The mechanism by which CRP converts to other forms has been discussed by
others. pCRP dissociates on lipid monolayers that consists of egg PC/lyso PC into
subunits as shown by Wang, et al in 2001[22]. As illustrated in Figure 2, pCRP loses its
5

pentameric structure and has a conformational rearrangement when it binds to an
endothelial cell membrane, forming mCRP that deposits in the blood vessel walls[23].
Moreover, pCRP changes conformation and transforms to a modified form under acidic
pH conditions that mimic the environment of the inflammation sites[24].

Figure 2. Conversion of pCRP.
Illustration of pCRP conformational changes upon its binding to a cell surface.

Beyond lipids, CRP also has well described protein binding abilities. CRP
interacts with various complement proteins such as C4 binding protein and factor H
which leads to the activation of the complement pathway through its binding to one
molecule of C1q per two adjacent molecules of CRP bound to a ligand[9]. Research
shows that mCRP which forms due to the disruption of the structure of pCRP using urea
is able to bind factor H and C4BP. However, native pCRP did not bind. In addition to
complement proteins, integrins have been identified to be binding partners for CRP[8].
6

Two novel receptors for mCRP were discovered and their binding linked to the proinflammatory action of mCRP binding to U937 cells. In contrast, pCRP showed less
effective binding to these integrins, which was attributed to an increased steric hindrance
due to size[8].
Cholesterol has also been identified as a novel ligand for CRP. The presence of
cholesterol binding domains within CRP suggests that the non-esterified cholesterol
content on the LDL surface has a role in CRP binding to modified LDL.[25] CRP has
been shown to opsonize native LDL which may play a role in foam cell formation and
atherogenesis[26].

1.2. C1q
C1q is an early component of the classical complement pathway and is known to
bind CRP. It is a well-recognized protein of the innate immune system[27]. C1q is a 460
kDa protein formed from six hetero subunits with each unit containing collagen-like
trimeric helical fibers. Each of these subunits ends with a C-terminal globular region
which binds to the apoptotic cell surface. C1q participates in the maintenance of the
immune tolerance via phagocytosis[28].
Previous studies have shown that C1q recognizes and binds to the
phosphatidylserine (PS) exposed on the surface of apoptotic cells through its globular
region at an early stage of apoptosis and allows for efficient apoptotic cell clearance. The
dissociation constant for the interaction of C1q globular regions with PS is 7x10-8 M. C1q
has showed to bind to blebs isolated from apoptotic cells and activates the complement
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pathway. The C1q globular region forms a complex with phosphoserine through the
interaction with subunit C of the globular region[28].
CRP binding to C1q has been showed to trigger the activation of the classical
complement pathway. The binding site of C1q on CRP was defined by Agrawal in 2001.
Research showed the Asp112 and Tyr175 residues are important for the C1q binding site
located at the end of the open side of the cleft on the promoter on the pentameric face
opposite to the PC binding site[29]. The dissociation constant for the interaction of C1q
with pCRP was determined to be 1.45 nM[9].

1.3 Membrane Curvature
Lipids and proteins are involved in membrane deformation and curvature. Thus,
changes in the lipid composition can cause membrane curvature and influences the
morphology of the membrane26. Lysophosphatidylcholine (LysoPC) tends to form an
inverted cone shape and generates positive curvature upon its addition to the lipid
bilayer12. LysoPC is produced as a result of phospholipid hydrolysis by the phospholipase
enzyme A2 in position 2 of phosphoglycerides27. Cellular membranes have different
compositions of lipid that vary throughout the cell. LysoPC is a naturally occurring
detergent that accounts for ≤ 3% of the lipid bilayer. The outer leaflet of a eukaryotic
plasma membrane is mainly composed of phosphatidylcholine (PC) which makes up
more than 50% of the phospholipids. In contrast, the cytosolic leaflet of the membrane is
enriched with phosphatidylserine (PS) and phosphatidylethanolamine (PE) 26.
The presence of lysoPC has long been known to enhance CRP binding to
damaged cell surfaces or on the surfaces of artificial bilayers. Previous work showed that
8

the incorporation of lysoPC to PC liposomes led to a change in the geometry of the lipid
model and caused a mismatch in the lipid bilayer that makes PC head groups more
exposed and accessible to CRP to bind[18]. Binding between CRP and lysoPC has an
impact on atherosclerosis[30]. CRP complexed with lysoPC has been shown to restrain
pro-atherogenic effects on macrophage cells which in turn may delay the atherosclerosis
progression.
Phospholipids with two saturated acyl chains exhibit a cylindrical shape, inducing
no curvature. Cone shaped lipids form if the head group is significantly smaller than the
acyl chain area and lead to the generation of negative curvature (concave) with a smaller
surface area. This forces the head groups to be close together against electrostatic
repulsion and cause steric hindrance12. This configuration is energetically unfavorable in
biological systems and can be stabilized by changes in lipid composition and the presence
of certain proteins at curved regions, which facilitate protein binding to accommodate
membrane deformation. Phospholipids that have a smaller acyl chain area than the head
group form an inverted cone shape and generate an area of positive curvature (convex)
with packing defects in the positive face12. The density of the hydrophobic defects would
increase as a result of membrane bending, and the increasing in the surface area of the
positive face will cause the hydrophobic tails to be exposed to the aqueous environment
which is an entropically unfavorable situation. Increasing the density of the defects leads
to the recruitment of large densities of hydrophobic molecules, 27 such as lysolipids that
have single tails to fill the gaps and stabilize the hydrophobic defects. Figure 3 illustrates
the structure of these lipids.
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Some proteins, including BAR domains and amphipathic helices, are known to
bind to curved membranes. Extreme membrane curvature within the cell can occur in
different structures such as the golgi, endoplasmic reticulum, microvilli and the plasma
membrane26. Plasma membrane curvatures play a vital role in cellular function.

Figure 3. Chemical structure of lipids and dye labeled lipid used in this work.
A) POPC [31], B) lysoPC[32] , C) MB-DHPE[33].

Beyond lipids, proteins are also involved in membrane deformation generating
positive and negative curvatures. Amphipathic helices that have one polar charged face
and one hydrophobic face promote membrane curvature via asymmetric insertion into
one leaflet of the membrane, which causes a wedge in the membrane and generates
10

curvature. The hydrophobic face dips into the tail section of the bilayer while the polar
face interacts with the polar head group of the membrane[34].
Another mechanism by which cells deform lipid membranes is through the use of
proteins. Scaffolding by proteins that have a rigid structure is one of the mechanisms that
influence membrane curvature. Common examples of these proteins are the dynamin
family of proteins that bind to inositol lipids and constrain tubular shape in the
membrane. BAR domain proteins and banana shaped dimer proteins are considered to be
sensors for highly positive curvature. These proteins bind strongly to highly curved
membranes due to an increase in the area of electrostatic interaction and a matching of
the intrinsic curved area of the protein with the area of curved membrane. Another aspect
of BAR proteins is their interesting interaction with the N-terminal of an amphipathic
helix (N-BAR domains) which induce positive curvature upon their insertion into the
lipid bilayer.
Due to the complexity of the biological cellular membrane, it is a challenge to
study how the membrane curvature and lipid shape affect molecule binding. Moreover, it
is difficult to separate the shape of the membrane from the chemical compositions within
the cell. Therefore, different methods have been proposed to mimic cellular membranes.
One of these established methods uses a single liposome curvature assay (SLiC) to study
membrane curvature sensing of biomolecules25. In this assay, liposomes of different
curvature were labeled using a fluorescent lipid and immobilized on a glass surface. The
size of the liposomes was determined from the relative fluorescence. The protein of
interest was labeled with a different fluorescent dye and the density of bound protein was
calculated from the fluorescence intensity extracted from the images taken by confocal
11

microscopy. The advantages of using this assay is to exclude the ensemble averaging
error which can arise when polydispersity exists. The major disadvantage is that the
liposomes are isolated, so the bound molecule cannot undergo dynamic exchange along
the surface as in the plasma membrane.
Another group used a wavy glass substrate with continuous positive and negative
curvature26. The liposomes were deposited on the surface to form a supported lipid
bilayer (SLB). The advantage of using this method is that it has a transition between the
area of positive and negative curvature. One disadvantage is that this method requires two
different processes to characterize the curvature and to visualize the bound protein which
requires another method to correlate them. The main disadvantage is that the lacking of
highly curved regions. Moreover, preparing the glass requires high temperature and using
a prefabricated mold which makes changing the topology of the glass to be used in
different experiments difficult.
To overcome these limitations, our lab has developed a cell membrane mimic
biosensor which is done in a way that allows us to separately change the shape and
chemical compositions[35]. This is one of the main advantages of the system since it is
challenging to do that in the biological system. Also, the spatial resolution between the
protein of interest and the sites of curvature can be achieved by using this biosensor. The
sites of curvature in this model are separated, so the equilibrium dynamic between the flat
region of the membrane and the sites of curvature was permitted which mimic the blebs
surface in the cells. This will help us to understand how CRP recognizes apoptotic cells
and oxLDL but not healthy cells and intact LDL. Also it will help us to know what causes
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the CRP conversion to mCRP which in turn binds C1q and leads to the activation of the
complement system. Moreover this assay will allow us to know if the membrane shape
affects CRP function.
Briefly, the SLB was formed over fluorescent polystyrene nanoparticles 40 or 100
nm diameter that were deposited upon a flat glass surface. Liposomes were prepared by
probe sonicating lipid films and lipid bilayers were created when liposomes fused with
the surface[35]. Figure 4 shows the biosensor with the regions of positive, negative, and
no curvatures. Fluorescent nanoparticles with different radii are used to control the extent
of curvature.

Figure 4. Cell membrane mimic biosensor model.
Lipid bilayer formed on the top of fluorescence nanoparticles showed regions of positive,
negative, and no curvature. Note that the lipids and nanoparticles are not drawn on the
same scale.
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1.4 Overview
This dissertation is divided into five chapters. Chapter two describes
Characterizing the membrane curvature assay and discuses in details the quantitative
analysis methods and programs that we used to quantify the data. It also focuses on
investigating how lipid compositions and CRP forms affects binding to curvature.
Chapter three focuses on using cellular membrane to characterize CRP binding to
apoptotic cells using MES-SA cells. Chapter four discusses using fluorescence assays to
characterize CRP conformational change. Finally, chapter five summarizes the major
results.
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CHAPTER TWO
2.1 Conformational Changes in C-reactive Protein Affect Binding to Curved
Membranes
This Chapter details the preparation of the curved supported lipid bilayer (SLB) to
investigate whether or not CRP preferentially binds to curved membrane. The SLB
enables us to separately quantify how the lipid composition and membrane shape affects
CRP recognition membrane. In addition, the different conformations of CRP (pCRP and
mCRP) affecting its binding to curved membranes was characterized. Fluorescence
recovery after photobleaching technique (FRAP) was also used to test the fluidity of the
lipid to ensure that the SLB mimics the biological system.
It has been shown that the conformational changes in CRP affect protein-protein
interactions, but little attention has been given to how protein conformational changes
affect lipid binding. It is interesting to note that PC is the predominant lipid headgroup in
the outer leaflet of cell membranes, yet CRP does not bind PC present on the surface of
healthy cells. Beyond Ca2+, it is not clear what is needed for CRP to bind to lipid
membranes. Past work has shown that lysoPC and oxidized PC are recognized by CRP.
Both of these lipids are common in damaged membranes, like apoptotic cells, but less so
in healthy cells. Others have shown using mimics of LDL that neither lysoPC nor oxPC
are needed; instead, CRP can recognize PC when it is presented on very small (diameter
<30 nm) nanoparticles[21]. In this work we show that the shape of the membrane can
15

recruit CRP; curved membranes bind more CRP. Modified CRP binds curvature, but the
soluble pentameric CRP does not over the range of curvatures tested.
2.2 Materials and Methods
2.2.1 Supported Lipid Bilayer
Lipid films in this study were prepared by using 1-palmitoyl-2-oleoyl-sn-glycero3-phosphocholine (POPC) (Avanti Polar Lipids, 850457C) as the main component. In
addition lysoPC (Avanti Polar Lipids) and marina blue 1,2-Dihexadecanoyl-sn-Glycero3-Phosphoethanolamine (MB-DHPE) were used. The molar ratio of these components
are varied as desired.
Our lab has developed a supported lipid bilayer (SLB) membrane mimic as
described previously[35].The SLB was formed over fluorescent, carboxylate-modified
polystyrene nanoparticles (FluoSpheres, Life Technologies;40-100 nm diameter) or over
a flat surface. The nanoparticles were first diluted to (1:1000) in deposition buffer and
sonicated in a bath sonicator for 15 minutes. Then, the second dilution of the sonicated
nanoparticles was made to a ratio of (30:700) before their deposition onto the 8 well plate
(Lab-Tek® Chambered Borosilicate Coverglass System, Thermo Fisher). 100 µl of the
diluted nanoparticles was added to each well and incubated for 30 minutes at room
temperature. After deposition, the nanoparticle solution was removed from the plate prior
adding the lipid. Lipid compositions consisted of PC, lysoPC, and MB-DHPE were
dissolved in filtered chloroform and stored at 4 ⁰C. PC (85% or 98%), lysoPC (14% or
3%), and MB-DHPE (1% or 2%) were combined as desired in batches with a total of 250
nmol and then dried under vacuum overnight to remove the chloroform. Upon use, a vial
is filled with 2 mL of buffer (2 mM CaCl2, 30mM HEPES, 140 mM NaCl or 2 mM
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CaCl2, 30mM PIPES, 140 mM NaCl pH 6.4) and was probe sonicated for 15 minutes.
100 μL of sonicated lipid solution was deposited in an 8 well plate and incubated at 37 °C
for 1 hour. 50 μg/mL CRP or 50 μg/mL mCRP were incubated with the lipid bilayer at 37
°C for 2 hours. Primary anti-C-reactive protein (C6), mouse IgG monoclonal antibody
(Santa Cruz Biotechnology) and secondary goat anti-mouse immunoglobulin G with
Alexa 488 (Life Technologies). Primary and secondary antibodies were pre-incubated
together in 1:1000 ratios for 30 minutes at room temperature. 100 μl of pre-incubated
antibody solution was added to each well. Imaging was done on both total internal
reflection fluorescence (TIRF) microscopy and laser scanning confocal microscopy.

2.2.2 Preparation of mCRP
Modified CRP (mCRP) was prepared by treating native pCRP with SDS diluted
to 0.01% in HEPES buffer (30mM HEPES, 140mM NaCl, 2mM CaCl2, or 30mM
HEPES, 140mM NaCl, 2mM CaCl2, pH 6.39) and heating it at 80⁰C for an hour. pCRP
was diluted to a final concentration 100 µg/mL. The conformational state of CRP was
determined by using native polyacrylamide gel electrophoresis due to the different
properties of pCRP and mCRP including running differently on a gel.

2.2.3 Image analysis of flat membranes
To analyze the binding of CRP to the membrane, Image J was used to identify
spots in the protein channel that were saturated. Then, MATLAB was used to find the
average intensity of the image without including the saturated pixels or the pixels that had
an intensity of zero, which were the bright spot that were cut.
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2.2.4 Location guided averaging analysis
Computational analysis of the images was done using location guided averaging
analysis procedure in MATLAB statistical software. To find locations of curvature
marked by red fluorescent nanoparticles, spots-finding methods were used based on
freeware designed from the methods of Crocker and Grier[36]. The MATLAB code for
these are found on the website by Blair and Dufrense[37]. Only the spot finding portion
of the code was used for this work. Location were excluded if they were 9 pixels of
another location or within 12 pixels of the image edge. Square regions of 25 by 25 pixels
were cropped from images of the nanoparticles channel which represents the curvature
location. The same region of corresponding locations in the protein channel were also
cropped yielding pairs of images. All the cropped regions in each channel were averaged
using ImageJ software to obtain a single image of 25 by 25 pixels of all the stacks. From
the pairs of images, we measured the distribution of 1) Pearson’s correlation coefficients
and 2) intensity in the 5 pixels center minus a local background consisting of an annulus
1 pixel wide with a diameter of 13 pixels (ΔF). From the average of the green cropped
images, a radial average was calculated. This is done by averaging all pixels that are a
specific distance from the center pixel. For example, there are 4 pixels that reside one
pixel (124 nm) away from the center (green squares) and these are averaged to give the
second data point. Four pixels that reside 175 nm from the center are averaged to give the
third data point and so on. MATLAB code for the radial averaging function is available
upon request. The correlation function calculation was obtained Dr. Justin Taraska[38].
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dF and radial plot measurements have been used by others to quantify the amount of the
protein at region of interest[38], [39].
The Pearson correlation coefficient (PCC) is a well-established method to
quantify the colocalization degree between two fluorophores from a pair of images. It has
been used to map protein association with exocytic vesicles and endocytic structures[38],
[39]. PCC has range from +1 to -1, where +1 denotes strong positive correlation, -1
strong negative correlation, and 0 indicates the absence of relation.
To calculate PCC, small regions (25x25 pixels) are extracted from the
nanoparticle image (red) along with the corresponding regions from the proteins image
(green). As a control, random positions are selected, cropped, and processed in the same
way. Then, all images are first normalized by subtracting the average. A deviation from
the average is a fluctuation. If the fluctuations in one color match the fluctuations in
another color then that is a correlation. After subtraction, the green image was multiplied
by the red (each pixel is individually multiplied) then the average of all 25 x 25 pixels
was divided by the average intensity of individual images as shown in the following
equation:

𝑟=

∑(𝑅𝑖 −𝑅𝑎𝑣 )∙(𝐺𝑖 −𝐺𝑎𝑣 )
√∑(𝑅𝑖 −𝑅𝑎𝑣 )2 ∙∑(𝐺𝑖 −𝐺𝑎𝑣 )2

Equation 1

When comparing different sized curvatures the surface area difference of the lipid
bilayer was corrected as follows: the structure of the curvature was estimated to contain
two parts: 1) a cylinder with a height equal to the radius of curvature (ROC) and a
diameter of 2 times the ROC and 2) a hemisphere with a radius equal to the ROC sitting
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on top. The amount of surface area normally present in a flat bilayer is equal to a circle
with a radius equal to the ROC. The difference between the two is the increase in surface
area due to the presence of curvature. For an ROC of 25 nm, the increase in surface area
is 2-fold. For an ROC of 55 nm, the increase in surface area is 4.84-fold. This correction
is performed in Figure 22, where different curvatures are directly compared.

2.2.5 Confocal microscopy
Laser scanning confocal microscopy is a powerful tool that illuminates a small
region of specimen by utilizing a small pinhole aperture that allows just for the light
comes from the area of interest to pass throw it and rejects the out of focus light. In this
work, the Olympus FV 1000 laser scanning confocal microscopy was performed and a
100x oil objective (2x zoom) such that one pixel was equal to 124 nm and with numerical
aperture (NA= 1.4). Three channels, blue, red, and green were used to sequentially excite
the DHPE-Marine Blue with 405 nm with an emission window from 42 5nm to 475 nm,
red nanoparticles were excited with 594 nm with an emission window from 575nm to 675
nm, and CRP with 488 nm diode laser with an emission window from 500 nm to 545 nm,
respectively. The speed of the scan was 12.5us/pixel.

2.2.6 TIRF Microscopy
Total internal reflection fluorescence microscopy (TIRF) is a method primarily
used to illuminate the fluorophores that are very close to the adherent cell surface or
coverslip sample within 100 nm with an exponentially decreases in the excitation
field[40]. The advantages of using TIRF are to reduce the background fluorescence due
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to reducing the intensity of the fluorophores that away from the coverslip. Moreover,
highlighting the events close to coverslip-sample interface. To achieve TIRF, the angle of
incident ϴ must be larger than the critical angle ϴc as well as the refractive index of the
glass n2 should be greater than the refractive index of the sample n1.

2.2.7 Fluorescence recovery after photo bleaching (FRAP)
Fluorescence recovery after photo bleaching is an optical technique intended to
use for Characterizing lateral diffusion of lipids within a cellular membranes[41]. To
mimic biological membrane, the supported lipid bilayers formed in our lab should be
fluid. To examine that, a circular region of 125 pixels by 125 pixels (ROI) was bleached
using laser beam at 100% with 405 nm wavelength by laser scanning confocal
microscopy. The emission was detected from 425nm to 475nm. Three initial frames were
imaged before the photo bleaching, seven frames were taken after bleaching the bleached,
and the total of 40 frames were imaged to obtain the recovery. The frames were taken at 1
frame per 0.5 s. The speed of the scan for imaged frames was 2 µs per pixel. To analyze
FRAP images, Image J and GraphPad Prism were used.
The average intensity of the photo bleached area (ROI) for all images was
corrected to the intensity of a region apart from ROI (reference area). The mean intensity
of ROI measured in each experiment was normalized. The intensity of the first image was
set to 1 since it has a highest value in image series. The lowest value was set to 0 which
represent the intensity of the frame immediately followed the step of bleaching.
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2.3 Results and Discussion
The main goal of our work is to detect what recruits CRP to bind the lipid
membrane and determine how the conformation of CRP affects binding. To do so, two
factors were addressed, the lipid bilayer composition and the degree of the membrane
curvature. The membrane curvature assay used in these experiments allows for control
the composition of the bilayer independently from the bilayer curvature. First, we
examined the effect of introducing lysoPC to the membrane containing POPC, which is a
CRP binding site as shown in figures 4 and 5. Second, we tested the effect of membrane
curvature on recruiting CRP.
In order to mimic the biological system, it is very important for the SLB to be
fluid. Therefore, the lipid fluidity was tested using FRAP technique before all the
experiments were performed.

2.3.1 Fluid lipid on a patterned substrate
FRAP experiments were performed to measure the MB-DHPE percent recovery,
diffusion constants, and mobile fraction on a flat surface or curved membrane (40nm,
100nm nanoparticles). ImageJ was used to retrieve FRAP data as described previously in
section 2.2.6. Briefly, a region with diameter (125x125 pixels) was bleached using 100%
laser power. Then lipid recovery was obtained by measuring a total of 40 frames.
After correcting for photobleaching as described above in method section, the
following equation was used to fit the data to a curve.
𝐹𝑡 = 𝐹0 + (𝐹∞ − 𝐹0 ) ∗ (1 − 𝑒 −𝑘𝑡 )
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Equation 2

Ft, 0,  represents values of fluorescence at given time, initially, and equilibrium,
respectively. Then the following equation was used to directly calculate the half time

𝜏½ =

𝑙𝑛(2)

Equation 3

𝑘

The diffusion constant, D, is related to the square of radius, r, of the bleached
area, the half time, 𝜏½ , and a constant of the bleach shape, γD, as:
2

𝐷 = (𝑟 ⁄4𝜏 )𝛾𝐷
½

Equation 4

A representative FRAP series of MB-DHPE is illustrated in
Figure 5. Frames were taken at 1 frame /1.25 s.
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t= -3.75s

t=0.0s

t=1.25s

t= 5.0s

t=20.0s

t=45.0s

Figure 5. Fluidity of lipids measured by FRAP technique.
Series of MB-DHPE lipid FRAP images show intensity recovered in the bleached circle
region in time. The bleach frame is at t=0.00s. The frame rate is 0.8 frame/sec. Images
were corrected for overall photobleaching and the data was used to calculate lipid
fluidity parameters ( Figure 6).

FRAP was also used to test the fluidity of MB-DHPE on variety of curvature size
using nanoparticles varied in diameter (45 nm, 100 nm), and a flat surface. The fluidity of
MB-DHPE on POPC bilayers, POPC containing 3% of lyso PC bilayers, and on flat
surface of POPC were tested. The recovery, diffusion constant, and mobile fraction are
shown in figures 6, 7. Mobile fraction was obtained by dividing the average normalized
intensities of the final three frames by the average intensities of the first three frames
before photobleaching.
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Figure 6. Lipid fluidity is measured by FRAP technique.
A) Average recovery of normalized intensity of lipid bilayers contains 98% POPC, 2%
MB-DHPE are shown for 100 nm, 45 nm, and flat. The data shows the fit of 5, 3, and 3
experiments collected for 100 nm PC, 45 nm PC, and flat PC membranes respectively.
B) Average recovery of normalized intensity of lipid contains 95%POPC, 3%lysoPC, 2%
MB-DHPE are shown for100nm, 45nm. The data shows the fit of 4, and 4 experiments
collected for 100nm PC/lysoPC, and 45nm PC/lysoPC membranes respectively.

FRAP data of the various recoveries of different lipid mixtures on either flat or
curved surfaces is shown in

Figure 6. Unpaired t-test revealed no significant differences

between the recoveries over a curved surface with 100 nm and a flat surface (p = 0.1656)
figure 6 A and between the two curved surfaces (100 nm, 45 nm) (p=0.1491). The
recoveries of lipid bilayers containing 98% of POPC over a flat surface was significantly
higher as compared with curved membranes with 40 nm diameter (p = 0.0054) figure 6
A. The recoveries of lipid bilayers contain 95% of POPC, 3% lysoPC over curved
membranes (100 nm, 45 nm) showed no significant differences (p= 0.842) using unpaired
t-test.
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Figure 7. Lipid diffusion and mobility.
A) Comparing lipid fraction are not significantly different between the groups (p>0.05
ANOVA). Error bars represents SEM. B) Diffusion coefficient are not significantly
different between the groups (p>0.05 ANOVA).Data represents the average of 5,
3,3,4,and 4 experiments collected for 100 nm PC, 45 nm PC, flat PC, 100 nm PC/lysoPC,
and 40nm PC/lysoPC membranes respectively.
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The fluidity of different surfaces was not significantly affected by changing the
lipid composition and size of curvature. No significant statistical difference in diffusion
constant, and in mobile fraction were obtained between the groups (P-value > 0.05
ANOVA) (Figure 7). Comparison of mobile fraction and diffusion constant between flat
membrane and curved membrane is illustrated in Table 1.

Table 1. Comparison of Diffusion constant and mobile fraction between different lipid
bilayer
Membrane lipid

POPC bilayer

Diffusion constant (μm2/s)

Mobile fraction

Mean/SEM

Mean/SEM

0.566 ± 0.073

0.729 ± 0.037

0.594 ± 0.230

0.681 ± 0.046

0.638 ± 0.027

0.768 ± 0.032

0.516 ± 0.084

0.812 ±0.05

0.549 ± 0.046

0.849 ± 0.07

w/ 100 nm NPs
POPC bilayer
w/ 45 nm NPs
POPC w/lysoPC bilayer
w/100 nm NPs
POPC w/lysoPC bilayer
w/45 nm NPs
POPC bilayer w/o NPs

2.3.2 Influence of lipid type on CRP binding to a flat membrane
To test the effect of lipid type on CRP binding, pCRP or mCRP were incubated
for 2 hours at 37⁰C with flat lipid bilayer that contains 98%POPC and 2% MB-DHPE.
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BSA was used as a negative control. Briefly, mCRP was prepared in our lab as described
previously[42] by incubation of pCRP with final concentration of 0.01% SDS at 80 ⁰C for
one hour. The final concentration of pCRP was 50 µg/ml. mCRP runs as a monomer on a
native polyacrylamide (supplement figure 1).

Figure 8. Influence of lipid type on CRP binding.
Fluorescent images of BSA (A), pCRP (B), and mCRP (C) binding to supported lipid
bilayers contains 98% POPC and 2% MB-DHPE. CRP is labeled with primary D7
mouse antibody and secondary (Alexa-488 labeled anti-mouse monoclonal) antibodies.
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Figure 9. Average intensity of CRP binds to flat membrane.
Average intensity of BSA, pCRP, or mCRP binding to flat bilayers contains 98% POPC
and 2% MB-DHPE. N=24, 29, 19 images for mCRP, pCRP, and BSA respectively, 3
experimental days. Back ground intensity was not subtracted. Error bar is SEM.
Statistical significance was observed (p<0.05) between pCRP, mCRP, and between
pCRP, BSA.

Confocal images showed that the flat SLB membrane with POPC recruited pCRP slightly
less as compared with mCRP Figure 8B, C. Quantification of the image intensity using
MATLAB revealed that there is no significant difference for pCRP and BSA binding to
the flat membrane, while mCRP binds significantly more than pCRP and BSA with
p<0.05 (Figure 9)
.
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2.3.3 Incorporating lysoPC into flat lipid bilayer enhances pCRP binding
Since previous studies have indicated that the PC liposomes that contain lysoPC
enhanced CRP binding[43], we sought to test the effect of introducing lysoPC to the lipid
bilayer on the recruitment of CRP. The influence of introducing lysoPC at 14% to the
lipid bilayer containing 85% of POPC and 1% of MB-DHPE on CRP binding is shown in
Figure 10. Images acquired by using TIRF revealed an increase in CRP binding to the flat
membrane with lysoPC.

B)

A)

Figure 10. The effect of addition of lysoPC to POPC flat membrane on pCRP binding.
A) TIRF images showing CRP binding to A) flat membrane contains 98% of POPC and
B) flat membrane contains 84% POPC/ 14%lysoPC. Images are auto scaled.
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Figure 11. Average intensity of CRP binding to a flat membrane contains lysoPC.
Average intensity of CRP binding to POPC or POPC-lysoPC flat membrane with the
intensity of the antibody subtracted. N=12 images, 2 experimental days. CRP monoclonal
mouse antibody C6 was used. No significant statistical difference was detected
(p=0.299). The error is the SEM. Computational analysis was also performed to quantify
the effect of lysoPC on CRP binding

Figure 11. MATLAB was used to find the spots for both images and detect their
intensity. The intensity of saturated pixels which represents the cluster of the antibody
molecules was not included in the total average intensity of each image.
TIRF images and the statistical data reveal that the membrane containing lysoPC
recruits 50% more of CRP than the membrane that contains only POPC on flat
membranes. The average intensity of the background was subtracted from the average
intensity of CRP binding to both lipid membranes. Future work should be done to give a
better understanding of the statistical difference between PC and lysoPC.
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This finding is in agreement with previous work that showed incorporation of
lysoPC to PC vesicles promoted CRP binding[18]. This is also relevant to a previous
observation that showed association of CRP in vivo with membrane of altered or necrotic
cells but not with the healthy cells[44] . This can be interpreted due to the restriction
accessibility of polar PC head group to the water phase in intact membrane of healthy
cells and not been freely accessible to CRP to bind. This is supported by NMR data that
revealed the presence of intramolecular interaction between PC polar head group in
artificial PC bilayers[45]. Therefore, it was suggested by Volanakis that binding of CRP
to the PC polar head group in intact membrane requires disturbance in the bilayer
geometry. This was tested by incorporating of lysoPC to PC bilayer which enhance CRP
binding due to the relaxation effect that lysoPC cause to the restriction of accessibility of
PC head group[18]. LysoPC is a single tail lipid tends to form an inverted cone shape and
creates positive curvature.
Beyond assessing the effect of the flat membrane on CRP binding, we sought to
determine whether curved membranes enhance CRP interactions with lipids using our
membrane curvature assay described in Chapter 1.The following section illustrates in
details the techniques that used to analyze the data.

2.3.4 Quantitative analysis of curved supported lipid bilayers
To determine whether or not CRP preferentially bound to curved membranes,
supported lipid bilayers were created over a nano-patterned surface as described in
methods section. Briefly, fluorescent nanoparticles were deposited at a density of 0.010.05 nanoparticles/µm2. CRP was incubated with the curved membrane surface and
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labeled with green fluorescent antibodies. Two color, confocal imaging was performed to
determine whether or not CRP bound to curved membranes. The red fluorescent
nanoparticles mark locations of membrane curvature (Figure 12A), as demonstrated in
previous work[35].The green fluorescent channel relates the amount and location of CRP
(Figure 12B). The lipid bilayer is composed of MB-DHPE (2%) and POPC (98%), a
common lipid on the cell surface, with regions of curvature that have a radius of
curvature (ROC) of 55 nm.
To quantify imaging data, nanoparticles were identified using a spot finding
algorithm as described in method section. Nanoparticles that were separated by more than
9 pixels from other nanoparticles and more than 12 pixels from the edge of the images
were cropped to 3.1 µm x 3.1 µm (25 x 25 pixel) images. The same locations were
cropped from the CRP channel and three examples of single cropped images are shown in
Figure 12C. The average of the nanoparticle images shows a spot in the center, as
expected. The average of the CRP images also contains a spot, but when random
locations are selected or BSA is used instead of CRP, no spot is detected (Figure 12C).
This object-based method of data analysis yields pairs of images that can be further
analyzed to obtain distribution information or averaged to obtain bulk information.
Because nanoparticles are very bright relative to the background and
monodisperse in both size and intensity, it is straightforward to automate the
identification of curved membrane locations. This is less true of CRP images. The
variability in protein number yields a wider range of intensities and a more subjective
measurement if spots were counted from this channel first. The identification of regions
of curvature first allows us to automate our analysis using object-based or location33

guided colocalization methods[35], [38], [39]. From individual pairs of images the
Pearson correlation function was calculated to relate how similar the two images are, with
-1 being images that are opposites and +1 being identical. The distribution of correlation
values is plotted as a histogram Figure 12 D and very little is observed to be correlated in
samples containing pCRP and curved POPC bilayers, Figure 12 D, black bars. Random
positions have a similar distribution, magenta curve.
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Figure 12. Description of the quantitative analysis of curved supported lipid bilayers.
Supported lipid bilayers were created on a surface containing red fluorescent
nanoparticles then imaged after incubation with CRP. A) Red fluorescent nanoparticles
images mark sites of curvature. B) Green fluorescently labeled protein (pCRP) is imaged
separately. Red positions are located using spot finding algorithms and positions are
shown with circles. C) The positions that are > 13 pixels from the image edge and >9
pixels from another position are cropped to a 25 x 25 pixel region, where one pixel = 124
nm. The cropped locations are labeled with magenta circles 1-6. The same locations are
cropped from the green image, shown in yellow circles 1-6, yielding pairs of images.
Random positions are selected and cropped as a control D) The Pearson’s correlation
coefficient is calculated for image pairs and a histogram of all pairs of images is plotted
for pCRP at regions of curvature (black) and pCRP at random positions (magenta
dashed line).
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The correlation function is useful for colocalization measurements, but the
intensity information is lost so we performed another measurements that retain
information related to the amount of protein present at curvature. All cropped, green
(CRP) images (n=3297) were averaged and a radial plot of the intensity as a function of
the distance from the center pixel was measured as shown in Figure 13.

Figure 13. Radial plot calculation.
A radial plot of the average images is calculated in MATLAB by averaging all pixels that
are a certain distance from the center pixel (shown in magenta). There are 4 pixels that
reside one pixel (124 nm) away from the center (green box), and these are averaged to
give the second data point (green arrow). Four pixels that reside 175 nm from the
center (blue box) are averaged to give the data point shown beside the blue arrow and so
on. The height of this plot at 0 nm is related to the amount of protein bound to
nanoparticle positions. The offset at distances far from the center is related to the amount
of protein that binds flat membranes, more than 1 µm away from curvature. The
difference between the height and the offset, is related to how well the protein senses
curvature relative to flat membranes. Background intensity was subtracted using the
average intensity of the tail from the CRP monoclonal C6 antibody radial plot. The error
is the SEM and it is smaller than the data points.
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This is done by averaging all pixels that are the same distance from the center, as
described in the figure caption and methods. After subtracting the background intensity,
the intensity of samples lacking green fluorophores, there are two pieces of information
in this plot: the height and the offset. The height is a measure of the amount of
fluorescence at regions of curvature and the offset is a measure of the fluorescence due to
binding to flat membranes. This method of analysis and these three measurements are
used to quantify how the lipid composition, protein conformation and membrane shape
separately affect CRP recognition of membranes.

2.3.5 CRP conformation affects binding to curved membrane
It is well known that the conformation of CRP affects binding to downstream
proteins, such as C1q and Factor H [3]. Here we tested whether CRP conformation
affects lipid binding to both curved and flat regions of membrane. Supported lipid
bilayers containing 98% POPC and 2% MB-DHPE were created over top of a fluorescent
nanoparticle patterned surface (ROC = 55 nm) then incubated with CRP and CRP
antibodies. The modified form of CRP (mCRP) was made as previously described. In this
preparation, the tertiary structure remains intact as demonstrated by the ability of mCRP
to bind downstream partners of the complement immune response in a way that acid
treated or fully denatured CRP does not[42]. Visually, mCRP shows high colocalization
to nanoparticles sites and is also present in flat regions when compared to pCRP Figure
14A. The average of the cropped, nanoparticle images shows a spot in the center, as
expected. All images, except the red fluorescent nanoparticle image, are scaled
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identically and linearly for direct comparison. A spot appears in the center for mCRP,
pCRP, samples with no CRP (and only antibodies, termed “none”), but not for samples
where the surface has been blocked with BSA instead of CRP or when random regions
are chosen instead of nanoparticle regions.
To assess the interaction between CRP conformers and curved membranes
further, correlation coefficients were calculated from pairs of cropped images Figure
14B. mCRP (black bars) and pCRP (grey line) are different; mCRP has a higher
correlation to the nanoparticle positions, suggesting higher preference for curvature. The
average correlation coefficient is 0.29 for mCRP (Figure 14) and this is due to a large
diverse distribution (Figure 14B). pCRP has an average of 0.03, which is similar to
samples where no CRP has been deposited and antibodies alone accumulate at curved
membranes. Randomly chosen positions show near 0 correlation. The data are illustrated
in table 2.

positions

Cavg

STDEV

SEM

n

Curvature

0.29

0.26

0.004

3792

Curvature

0.03

0.14

0.002

3297

Curvature

0.04

0.16

0.004

1413

Random

0.0005

0.08

0.0024

1100

Table.2. Correlation coefficient values of CRP at sites of curvature
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Figure 14. Protein conformational effects
Modified CRP and native, pCRP conformations of CRP are prepared and incubated on
curved supported lipid bilayers, then imaged using confocal microscopy. A) Average
images of nanoparticles, mCRP, pCRP, samples with antibodies only (“none”), and BSA
blocked samples with antibodies only have been cropped from regions selected from
nanoparticle positions. Random positions were also selected and mCRP regions were
cropped from random positions (labeled “random”). The images are all scaled linearly
and identically. B) The distribution of correlation coefficients for pairs of cropped
images is measured for mCRP (black) and pCRP (dashed line). C) The average of the
distribution is plotted for mCRP, pCRP, images with antibodies alone (no CRP), and
CRP at random regions instead of curved membrane regions.
Modified CRP accumulates at curvature and the amount and distribution is
quantified by plotting the radial distribution from an average image (Figure 15). The
radial average of the cropped images shows that mCRP binds both flat regions, as
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observed by the offset, and nanoparticle regions, observed by the peak height, better than
pCRP.

Figure 15. Comparing the Radial average intensity of CRP conformers at ROC (55nm).
From the average images, the intensity is averaged radially to show the accumulation of
mCRP and pCRP in both flat (large distance and curved (small distance) regions.
Background intensity was subtracted using the average intensity of the tail from the CRP
monoclonal C6 antibody radial plot. The error is the SEM
The increase in fluorescence at curvature relative to background, ΔF, is calculated
from the height – offset for each cropped image, where the height is a pixel-weighted
average of the first two points in the radial curve. The offset is measured 6 pixels away
from the center, a distance greater than the spread of the intensity in the center but less
than the nearest neighbor distance. In Figure 16, the average of all cropped images is
plotted and ΔF is significantly higher for mCRP relative to pCRP.
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Figure 16. Average intensity of CRP conformers at sites of curvature.
The preference for curvature over flat regions, ΔF, is calculated from radial plots and the
average of the distribution is shown. In all bar graphs, the error is the SEM.

The mCRP form was able to bind membranes significantly more than the pCRP
form. This is likely due to hydrophobic regions of CRP being exposed once the pentamer
is broken apart. Hydrophobic proteins preferentially insert into membranes or aggregate.
In our work, we observe membrane incorporation and this membrane incorporation does
not require Ca+2. It is likely that any protein with hydrophobic parts exposed would show
binding to curvature. Intrinsically disordered proteins were recently discovered to induce
membrane curvature. Similarly, palmitoylated proteins show affinity for highly curved
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membranes[46]. To determine if this is a universal occurrence for any disordered,
anchored, or denatured protein requires further experimentation.
Figure 14 reveals that mCRP readily binds curved membranes, much more so
than pCRP, which hardly binds at all. Regions of curved membranes are thought to differ
from flat regions in the way that lipids are packed. Curved regions have defect sites –
sites where there is more space between headgroups than tails – which are thought to
allow exposure of the hydrophobic tails to the surrounding aqueous solution. Defect sites
are places on a membrane where protein and lipids can accumulate if there is a need for
hydrophobic interactions. Modified CRP, which is stabilized by SDS, likely has
hydrophobic portions exposed. Research demonstrates that mCRP likes to aggregate[47]
which usually occurs through hydrophobic interactions. Here, hydrophobic regions could
be stabilized by binding to defect sites, as observed by the high binding of mCRP, but not
pCRP to curvatures of 100 nm.

2.3.6 Lysophosphatidylcholine (lysoPC) increases CRP binding to curved membranes
The presence of lysoPC has long been known to enhance CRP binding to
damaged cell surfaces or on the surfaces of liposomes[48] . To investigate how changes
in the chemical composition affect CRP binding, supported lipid bilayers that contained
3% lysoPC, 2% MB-DHPE (to measure fluidity) and 95% POPC were created over a
nanopatterned surface where both flat and curved membrane regions were measured
simultaneously. Upon the addition of lysoPC, the Pearson’s correlation coefficient
increased for both pCRP and mCRP Figure 17 A, B. In both cases, there is an increase in
the distribution at larger coefficients. In Figure 18, the average correlation coefficient is
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shown relative to random positions and a dashed line indicates the position without
lysoPC. There is an increase by approximately 0.1 for both forms of CRP suggesting the
lysoPC enhances binding to curved regions.
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A

B

C

Figure 17. Lipid composition effects
CRP was incubated with lysoPC containing membranes (LysoPC:POPC:MB-DHPE at
3:95:2 molar ratio) that had regions of curvature (ROC = 55 nm). CRP (m and p
conformers) were incubated with the bilayers for one hour at 37°C and then imaged.
Images were cropped about nanoparticle positions and random positions and
quantification is described in Figure 12. From cropped images, the Pearson’s
correlation coefficient was calculated for A) pCRP (black bars) and B) mCRP (black
bars). The grey line in both plots denotes the distribution of the correlation coefficient in
membranes that do not contain lysoPC. C) The average value of the distribution with
SEM. The dashed line shows the average value when lysoPC is not in the membrane.
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To determine how much CRP accumulates at nanoparticle regions when lysoPC is
present, the intensity of CRP fluorescence is quantified .The height of the radial plot of
mCRP increases slightly as shown in Figure 18, where the black line is the radial plot
without lysoPC and the black circles are with lysoPC. The height of the radial plot of
pCRP at nanoparticles increases more, from 97 counts to 438 counts, where the grey line
is the radial plot of pCRP without lysoPC and the open circles depict the radial plot in the
presence of lysoPC.

Figure 18. Radial averages of mCRP and pCRP binding to sites of curvature.
mCRP and pCRP binding to lysoPC bilayers (red circles and blue circles, respectively),
mCRP (black dashed line) and pCRP (green dashed line) on bilayers without lysoPC.
The purple solid line is from random positions. Background intensity was subtracted
using the average intensity of the tail from the CRP monoclonal C6 antibody radial plot.
The error is SEM.
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The increase of fluorescence at nanoparticle sites (ΔF) also shows that pCRP
binding is affected by the presence of lysoPC as shown in Figure 19. Both the pCRP and
the mCRP changes are statistically significant (P <0.05), indicating that lysoPC serves to
increase binding of all forms of CRP to curved regions more so than to flat regions, but
affecting pCRP more than mCRP.

Figure 19. The average of the ΔF distribution.
ΔF for mCRP and pCRP with and without lysoPC at ROC 55nm. , ΔF, is calculated from
radial plots and the average of the distribution is shown. In all bar graphs, the error is
the SEM.
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The data indicated that the lipid composition also affects binding to both curved
and flat membranes. LysoPC is a marker for damaged membranes and the interaction
between CRP and lysoPC was first identified in the 1970s[18]. One advantage of the
experimental configuration is the ease at which lipid composition can be altered
separately from the membrane shape. In Figure 17, we show that lysoPC enhances
binding more at curved regions than on flat regions and enhances both pCRP and mCRP
binding. This is likely due to the accumulation of single tailed lipids at sites of
curvature[35]; there is a higher density of lysoPC at the curved regions to bind CRP.
Others have suggested that lysoPC introduces irregularities into artificial lipid
bilayers[18]and that these are essential to binding pCRP. The presence of lysoPC affects
pCRP more than mCRP, increasing the accumulation by 4-fold as opposed to a 10%
increase at curved membranes Figure 19, suggesting that mCRP associates in a way that
does not depend significantly on binding lysoPC, whereas pCRP association does. pCRP
likely interacts through headgroup interactions as others have observed on highly curved
membranes lacking lysoPC[21].

2.3.7 Membrane shape affects CRP binding
The shape of a membrane has been shown to affect protein binding for a variety
of membrane associated proteins, such as BAR domains[49], amphipathic helices[50],
[51], and lipid –anchored proteins[46], [52]. By decreasing the size of nanoparticles used
as a template for the supported lipid bilayer, higher curvatures (Rc = 27 nm) were
examined.
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Figure 20 shows how the Pearson’s correlation coefficient distribution is affected by
membrane shape for both conformations. The distribution shifted to higher, more
colocalized coefficients for pCRP Figure 20A, whereas the shift was to lower coefficients
for mCRP Figure 20B. In both figures the correlation coefficient between larger
nanoparticles and CRP is shown as a magenta curve and the correlation coefficient
distribution for smaller nanoparticles and CRP is shown as a bar graph.
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Figure 20. Membrane curvature effects:
CRP recruitment to curvature with a smaller nanoparticle support (d = 45 nm, ROC =
27 nm) was measured using confocal microscopy. Lipid bilayers contained 98% POPC,
2% MB-DHPE A) The Pearson’s correlation coefficient distribution for pCRP and
nanoparticle images, depicting the higher curvature (ROC = 25 nm, black bars) and
lower curvature (ROC = 55 nm, magenta curve) normalized correlation coefficient
distribution for 1574 and 3297 nanoparticle positions, respectively. B) The Pearson’s
correlation coefficient distribution for mCRP and nanoparticle images, depicting the
higher curvature (ROC = 27 nm, black bars) and lower curvature (ROC = 55 nm,
magenta curve) normalized correlation coefficient distribution for 1368 and 3792
nanoparticle positions, respectively.

The results were similar when 3% lysoPC was included in the bilayer Figure 21.
mCRP does not select for higher curvatures nearly as well as lower curvatures, however
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pCRP associates with higher curvatures better. The mechanism by which mCRP and
pCRP interact with membranes is likely different.

Figure 21. CRP recruitment to curvature:
CRP recruitment to curvature with a smaller nanoparticle support (d = 45 nm, ROC =
25 nm) was measured using confocal microscopy. Lipid bilayers contained 95% POPC,
3% LysoPC, 2% MB-DHPE A) The Pearson’s correlation coefficient distribution for
pCRP and nanoparticle images, depicting the higher curvature (ROC = 25 nm, black
bars) and lower curvature (ROC = 55 nm, magenta curve) normalized correlation
coefficient distribution. B) The Pearson’s correlation coefficient distribution for mCRP
and nanoparticle images, depicting the higher curvature (ROC = 27 nm, black bars) and
lower curvature (ROC = 55 nm, magenta curve) normalized correlation coefficient
distribution.

One key difference in the membranes that are formed over large nanoparticles (lower
curvatures) compared to smaller nanoparticles (higher curvatures) is the surface area.
When projected onto a 2D image, the larger nanoparticles contain 4.84 times the amount
of surface area than a flat region and the smaller nanoparticles contain 2 times the amount
of surface area (see Materials and Methods for the explanation). It is relatively
straightforward to correct for the surface area differences when measuring intensity
Figure 22. The intensity (y-axis) was corrected for surface area by dividing by
either 4.84 for low curvature membranes or 2 for high curvature membranes. After
measuring the surface area corrected increase in intensity at curvature compared to flat
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areas (ΔFSA), mCRP collects at larger nanoparticles (lower curvature) at a density greater
than the accumulation at smaller nanoparticles (higher curvature). However, pCRP shows
the opposite trend, in agreement with the work of others[21]. The shape of a membrane
clearly affects CRP binding and this depends on the form of CRP.
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55 nm

27 nm

Figure 22. The preference for curvature over flat regions (ΔFSA).
ΔFSA is calculated from radial plots (not shown) and normalized for differences in
surface area. The mean +/- SEM are plotted for all lipid, curvature and CRP
conformation. To correct for surface area differences, the values for higher curvature
were divided by two and the values for lower curvature were divided by 4.84 to compare
the protein density at curvature to that at flat regions. Grey columns correspond to
mCRP, white columns are pCRP. Striped columns contain no lysoPC, whereas the solid
columns contain 3% lysoPC. Antibodies used for these experiments were CRP
monoclonal C6 and CRP monoclonal D7 for curvatures with radii of 55 nm and 27 nm,
respectively. A supplemental figure with dot blots for these antibodies can be found in the
appendix.

The native form of CRP (pCRP) binds at a higher density to higher curvatures
than to lower curvatures both in the presence of lysoPC and without lysoPC in Figure 22.
This is in agreement with past work on CRP[21] and other proteins, such as
palmitoylated proteins[46], [52] and amphipathic helices[50]. In previous work on CRP,
very high curvatures (ROC = 10-15 nm) were tested and shown to bind pCRP better than
lower curvatures (ROC = 20-35 nm), however the lower curvatures likely bound pCRP to
a lesser extent based on the fact that CRP was activated in some way to be able to bind
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C1q after incubation[21]. All binding was Ca2+-dependent, indicating that the pCRP:PC
interaction was likely through binding of the PC moiety as opposed to an interaction with
the lipid tails. Curvature could enhance binding by facilitating multivalent
interactions[53] .To support this mechanism, recent work measured CRP binding
constants on an engineered surface where the distance between PC ligands was
varied[54]. In this work, the dissociation constant decreases by approximately 25-50%
when PC is separated by 1.0-2.0 molecules/nm2, a distance larger than the natural
packing of lipids on a flat membranes[55].Once PC groups are too far apart for
multivalent binding (>2.0 molecules/nm2), the dissociation constant increases again.
Regions of curved membranes are thought to differ from flat regions in the way that
lipids are packed and curving a bilayer would results in a larger spacing between lipid
head groups, also known as defect sites.
At lower curvatures (ROC = 55 nm) mCRP bound membranes significantly more
than pCRP. Other proteins, such as amphipathic helices, preferentially insert into curved
membranes through hydrophobic interactions with the defect sites that occur as a lipid
membrane bends around a curved surface [52]. Curved regions have defect sites, which
are thought to allow exposure of the hydrophobic tails to the surrounding aqueous
solution and potentially interact with hydrophobic proteins.
Defect site binding to membranes, alone, cannot explain the clear preference mCRP has
for larger curvatures
Figure 22. One mechanism by which a specific shape preference comes about is
from a 3D protein structure that has an intrinsic curvature, like a BAR domain[49] or a
clathrin coated pit[34]. These larger structures then prefer lipid membranes that match in
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shape to their intrinsic curvature. It is possible that mCRP could form larger aggregates
on membranes, as others have proposed[47], giving rise to a larger structure that has a
specific curvature preference. We see no direct evidence of aggregation in our assay. A
second mechanism for specific curvature sensing could arise from multivalent binding.
Recent work shows that CRP binds with different affinities based on the separation of PC
headgroups[54]. For a protein to detect curvature in this way would depend on retaining
some multimeric state. It is possible that higher order structures are what drive CRP
binding and this structures form better on membranes with a radius of curvature of 55 nm
as opposed to 25 nm. In the future, a wider spectrum of sizes could be studied to further
understand CRP binding.

2.4 Conclusion
In this Chapter, a nanopatterned substrate was utilized to introduce curvature into
continuous lipid bilayers for quantitative image analysis of CRP binding. One major
advantage of this assay is the ability to separately tune chemical composition and
membrane shape[35]. This work demonstrates that the conformational state of CRP
affects lipid binding. Monomeric CRP readily associates with membranes, favoring sites
of curvature over flat regions. Native, pCRP does not easily associate with membranes
until the curvature is high (ROC = 25 nm) or until lysoPC is introduced. CRP likely
recognizes damaged lipidic materials through a mechanism that combines PC binding by
pCRP and membrane insertion into defect sites, which stabilizes mCRP. Both of these
types of interactions are strengthened at sites of curvature.
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CHAPTER THREE
3.1 CRP recognition of apoptotic cellular membranes
CRP is known to bind to apoptotic cells to facilitate their clearance[56], and this
activity prevents autoimmune disease[57]. To do this, a possible conversion takes place
between two isoforms – pentameric CRP and modified CRP. This conversion affects CRP
binding to C1q, an established recognition protein of the innate immune system. However,
the triggers that cause pentameric CRP (pCRP) to convert to the modified form (mCRP)
upon binding to apoptotic cells is still not well understood[7],[19]. Moreover, the factors
that allow CRP to recognize and bind PC in apoptotic cells selectively compared to healthy
cells need to be established. Since both healthy and apoptotic cells have PC on their outer
leaflet, it is probable that another factor that helps CRP bind to apoptotic cells. There are
several differences between apoptotic and healthy cells. First, the physical structure of the
cell membrane varies as the apoptotic cells form cellular blebs (curved protrusions) during
apoptosis. Second, the distribution of lipid compositions between the inner and outer
leaflet of cell membrane is changed since the phosphatidylserine (PS) flip to the outer
leaflet during apoptosis[58].
We hypothesize that once CRP binds to the surface of apoptotic cells
conformational changes can take place that activate CRP-C1q binding. To test our
hypothesis we quantitatively measured CRP binding to apoptotic cells versus healthy cells.
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For our in vivo work, we used MES-SA cells, a human uterus sarcoma cell line, to
induce apoptosis using the drugs valinomycin and paclitaxel. After treatment, we measured
the binding of CRP using fluorescence microscopy. The cells membrane was visualized
using Annexin V, which binds to the phosphatidylserine present on the extracellular side
of the apoptotic membranes, and large blebs were identified by their shape. This work
included three stages, one where we measured whether or not CRP binds more to apoptotic
cells. Secondly, the binding of the C1q protein to apoptotic cells and the
immunofluorescence of C1q with CRP on apoptotic cells were measured. The research has
also advanced to examine the conversion of CRP from pentameric to monomeric form after
incubation with apoptotic cells for different amounts of time by utilizing a RNA aptamer
that specifically binds to mCRP but not pCRP[42], [59].

3.1.1 Apoptosis
Apoptosis is programmed cell death accompanied by morphological changes such
as cell shrinkage, chromatin condensation, and plasma membrane blebbing. Later, these
blebs separate from the dying cells as apoptotic bodies with their membranes intact and
then they are engulfed by macrophages[60]. Apoptosis differs from necrosis since necrotic
cells do not form blebs, and do lose their membrane integrity. This process starts with the
cytoplasm swelling and ends with cell lysis when cells release their intracellular
components that stimulate inflammation[61].
Another important feature of apoptosis is the flipping PS to the outer leaflet of the
plasma membrane, which is considered as a recognition ligand for neighboring cells. This
results in a quick phagocytosis to prevent inflammation. The fast uptake and removal of
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these cells with no release to their constituents leads to no inflammatory response[60].
Also, apoptotic cells can stimulate phagocytes to produce anti-inflammatory cytokines.
The mechanism by which PS translocate to the outer leaflet of the membrane is not
completely understood. Lipid asymmetry under normal conditions is maintained by the
activity of flippases and floppases between the outer and inner leaflet. However, during
apoptosis scramblase becomes activated which leads to loss lipid asymmetry and causes
PS to expose to the outer leaflet. Apotosis can also be detected by some proteins such as
AnnexinV which is shown to be exposed on the surface of apoptotic cells. Annexin V, is a
specific protein binds strongly to PS and helps to detect apoptosis[58].
In addition to PS flipping to the plasma membrane outer leaflet, the lipid
compositions of this outer leaflet also undergo specific changes during apoptosis. It has
been shown that the lipid order of the outer leaflet significantly changes during apoptosis.
The loss of lipid order has been connected with lipid scrambling and sphingomyelin (SM)
hydrolysis which cause SM to flux from outer to inner leaflet[62]. Apoptosis is initiated
through complicated, regulated machinery by activating Caspases, proteins degradation
enzymes.

3.1.2 Drugs used for Apoptosis
In this study, two different drugs, valinomycin and paclitaxel were used to induce
apoptosis. The first, valinomycin is a selective membrane transporter protein for potassium
ion K+ across the cell membranes. It is a cyclic antibiotic consists of 12 carbonyl groups
allows it to bind to metal ions and solvates in a polar environment. Valinomycin captures
K+ to its inner cavity and form complex. It also has isopropyl groups and methyl groups
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responsible for its solvation in non-polar environment. Therefore, in the membrane lipid
phase valinomycin complexed with K+ can be transferred into the other side of the cell[63].
It has been reported that valinomycin triggers mitochondrial permeability transition causes
intracellular acidification which activates cysteine active site protease causes degradation
of the nuclear proteins and chromatin condensation[64]

3.1.3 Paclitaxel (Taxol)
Paclitaxel is a chemotherapy drug that binds tubulin and protects microtubulin from
being disassembled by stabilizing them, and blocks G2/M phase in cell cycle[65]. The
mechanism by which Taxol induces apoptosis is still not very clear. It has been reported
that Taxol induced massive apoptosis in MCF7cells[66]. Taxol has been shown to
modulate the phosphorylation of some molecules and cycles in MCF7 cells that are
involved in apoptosis and cell proliferation. The significant elevation in the activities of
these molecules, ERK and p38 MAPK in cells treated with Taxol, leads to the suggestion
that these molecules mediated Taxol induced apoptosis in MCF7 cells. Previous studies
reported that ERK promotes apoptosis by inducing the release of cytochrome C which
enhances the activation of Caspases involved in apoptosis[67].

3.1.4 CRP binds to apoptotic cells and converts to mCRP
CRP has been shown to bind to apoptotic cells and consequently enhances the
activation of the classical complement pathway. It also promotes their opsonization and
phagocytosis by macrophages[56]. CRP could target many molecules on the surface of
apoptotic cells such as PC head groups, lysoPC, ox PC, and FcγRIII. Studies have also
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shown the binding of CRP to the membranes of cells or liposome will result in a rapid but
partial structural change of pCRP producing a hybrid molecule, membrane bound
molecule (mCRPm), and that retains a pentameric conformation with partial structural
changes[19]. mCRPm binds to C1q and leads to complement activation.
Research suggests that mCRP has a proinflamatory effect since it was bound to
membranes in atherosclerotic plaques, however healthy vessels have neither form of
CRP [6]. mCRP- HAECs interaction was mediated by mCRP insertion to the
membrane[68]. The nature of this binding was evaluated by washing the cells with high
salt, acid, or base to dissociate electrostatic adsorption, high affinity receptor binding, or
peripheral protein from cell membrane, respectively. mCRP interaction with HAECs was
not affected by any of these treatments. This indicated that mCRP binding was receptor
independent and likely driven by lipid interactions.
mCRP has been shown to bind to lipid raft microdomains in human aortic
endothelial cells (HAECs) with a binding affinity 20x more than pCRP[68]. This
interaction was mediated by mCRP membrane insertion instead of receptor binding using
the putative cholesterol binding sequence of CRP (aa 35-47) and the C-terminal
octapeptide (aa 199-206). This was characterized by pre incubation of mCRP with 3H12,
antibody that recognizes (aa 199-206) or with 8C10, antibody that recognizes (aa22-45)
which contains cholesterol recognition domain. Then mCRP complexed with the
antibody was injected under monolayer contains egg PC/cholesterol/SM (3:1:1) or egg
PC monolayer that does not contain cholesterol. Results from pressure measurements
indicate that mCRP complexed with 3H12 decreases binding of mCRP to the monolayer
with cholesterol by 60%, while 8C10 decreased by 40%.
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In addition to the proinflamatory effect, mCRP has showed to play dual role in
activation and inhibition of the classical complement pathway. mCRP binds to C1q, the
initiator of the classical complement pathway, on the damaged human cells surface and
necrotic heart tissue. This leads to trigger the activation of the complement pathway and
allows opsonization with C3b. C4bp, a regulator and classical pathway inhibitor, and
factor H, the alternative pathway inhibitor, were recruited to the damaged cells surfaces
by mCRP which leads to block the complement cascade progression and inhibit the
inflammation[69].

3.2 Material and Methods
3.2.1 Induction of apoptosis and CRP incubation
MES-SA cells were grown at 37°C / 5% CO2 in McCoy’s media supplemented
with 10% fetal calf serum, 100 μg/mL penicillin, and 100 μg/mL streptomycin. Cells
were incubated in DMSO or 100 μM valinomycin for 4 hrs. Hoechst 387 DAPI nuclear
stain was added to the cells and allowed to incubate for 5 minutes at 37⁰C. Then, cells
was incubated with Annexin V Alexa594 stain for 15 minutes at 37⁰C. Cells were fixed
by using 4% formaldehyde for 15 minutes and then washed 3 times with phosphate
buffered saline PBS buffer. Human CRP was purified from endotoxin by using
Endotoxin Removal Gel. 20 μg/mL CRP was added to both fixed control and apoptotic
cells and allowed to incubate for 45 minutes in the presence of Tris buffer with 1 mg/mL
BSA. Primary anti-CRP (C8), mouse IgG monoclonal (1:100000) (Santa Cruz) was
incubated for 20 minutes, then secondary goat anti-mouse immunoglobulin G with
Alexa-488 (1:100000) (Life Technologies, A 11005) were incubated for 20 minutes.
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Images were taken using an Olympus laser scanning confocal microscope. The
membrane of each individual cell was highlighted using free hand tool, then the intensity
of CRP was calculated by using this equation:
𝐶𝑅𝑃 𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 = 𝐶𝑅𝑃 𝐼𝑛𝑡𝑒𝑔𝑟𝑎𝑡𝑒𝑑 𝐷𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝐶𝑒𝑙𝑙 𝐴𝑟𝑒𝑎 −
(𝑀𝑒𝑎𝑛 𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 × 𝐶𝑒𝑙𝑙 𝐴𝑟𝑒𝑎)

Equation 5

3.2.2 Induction of apoptosis and C1q incubation
100 μM valinomycin dissolved in DMSO was used to induce apoptosis in MESSA cells for 4 hours. Control cells were exposed to an equal concentration of DMSO
(1:1000). Cells are then stained with cell mask in PBS buffer followed by the addition of
10 μg/mL Hoechst DAPI nuclear stain (Invitrogen), and incubated for 5 minutes at 37⁰C.
Cells were washed by PBS, and fixed by incubation with 4.0% formaldehyde for an hour
followed by washing three times with PBS. The apoptotic and control fixed cells were
incubated with C1q (10 μg/mL) for 30 minutes at 4⁰C. C1q was visualized using a
primary mouse monoclonal anti-C1q (ab714940) antibody and a secondary rabbit antimouse IgG Alexa 488 with a 1:1000 dilution.

3.2.3 Induction of apoptosis by using paclitaxel
Paclitaxel was diluted with DMSO to final concentrations of 700 nM or 900 nM.
Cells were incubated for 16 hours, and then stained with DAPI and annexin V Alexa594.
Control cells were exposed to DMSO with a final dilution (7:10,000) or (9: 10,000). Live
Cells were imaged using confocal microscopy.
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3.2.4 Aptamer detection of CRP conversion
MES-SA cells were incubated in 900 nM of paclitaxel for 16 hours. Afterward,
cells were washed 3 times with PBS buffer. 10 µg/mL of CRP or 10 µg/mL of mCRP
were added to apoptotic cells which had been plated in different wells at varying
incubation times. Protein incubation was done with Tris buffer with 1% BSA to block
nonspecific binding. mCRP was prepared by heating pCRP with 0.01% SDS at 80⁰C for
an hour. A RNA aptamer specific for mCRP (Integrated DNA Technologies, Coralville,
IA) and end labeled with Cy3 was reconstituted with DEPC treated water and stored at 20⁰C until use. The RNA sequence was 5′-Cy3-GCC UGU AAG GUG GUC GGU GUG
GCG AGU GUG UUA GGA GAG AUU GC- 3′. Next, cells were washed with PBS to
remove unbound proteins and then stained with DAPI stain followed by a 30 minute
incubation with the aptamer at room temperature. Finally, cells were washed with PBS
before imaging by confocal microscopy. Images were analyzed using ImageJ as shown in
Figure 27.

3.3 Determining incubation time for apoptosis
3.3.1 Visualization apoptotic MES-SA cells using Annexin V
Annexin V Alexa 594 is a protein that has high affinity to bind to
phosphatidylserine that flips to the outer leaflet of the plasma membrane upon
programmed cell death. This assay allows to visualize the membrane of the apoptotic
cells, blebs and quantify the percentage of apoptosis. Cells treated with 900 nM paclitaxel
overnight show higher binding to Annexin V Alexa 594 than cells incubated with 700 nM
of the drug (Figure 23). By counting the cells that were stained by annexin V Alexa594,
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the percentage of apoptosis of the cells incubated with 900 nM paclitaxel was
27.0%±4.24 (SEM) as compared with the 700 nM apoptotic cells which was 21.4%±3.37
(SEM) (Figure 23).
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A.

700nM Paclitaxel

900nM Paclitaxel

B.

Figure 23. Annexin V Alexa 594 binds to apoptotic cells.
Annexin V Alexa 594 binds to phosphatidylserine (PS) in live apoptotic cells (red). A)
Fluorescent images of annexin V binding to cells after treatment with paclitaxel
overnight. B) Percentage of apoptosis was measured by counting the cells that positively
stained with Annexin V. N=453 and 500 cells for control groups treated with 700nM and
900nM, respectively. For Paclitaxel groups, N=557 and 406 cells for cells treated with
700nM and 900nM, respectively.
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3.3.2 CRP binding to apoptotic cells
After exposing MES-SA cells to valinomycin, quantitative measurements of CRP
binding to the cellular membrane was done using ImageJ. The free hand tool in image J
was used to highlight the outline of the cells’ membranes and to measure the intensity of
CRP binding to each individual cell. Blebs of various curvatures can be seen in the
apoptotic cell. The percentage of the apoptotic cells was 30% as compared to the control
cells which was 6%. This was calculated by counting the cells that were stained by
Annexin V Alexa594. Using image J and a set of images, the average intensity of the
CRP binding the control cells was measured to be (2,798) with the standard error (252.1).
For the apoptotic cells, the average intensity was (4,089) and the standard error was
(654.4). (Figure 24). The intensity of the CRP was calculated by the equation 5 above.
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A.

B.

C.

Figure 24. CRP binds to apoptotic fixed MES-SA cells.
A.) Control Cells treated with DMSO. B) Cells after incubating with Valinomycin for
4hours. C) Apoptotic cell with blebs. Cells were stained with Annexin V that binds PS on
the outer leaflet of the cell membrane. Primary anti-CRP (C8), mouse IgG monoclonal
was used. Images were taken using confocal microscopy. Image C was taken by Kathryn
Palma.
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Figure 25. Intensity of CRP binding to control and apoptotic cells.
Average integrated Intensity of CRP binding to control and apoptotic cells. The antibody
background integrated intensity and areas of images that have no cells were subtracted
and calculated using (Eqn. 3). N= 103, 170 cells for control and apoptotic cells
respectively. No statistical significance was observed between control and apoptotic cells
using t-test. p=0.136.

3.3.3 C1q binding to apoptotic cells
C1q, an early component of the classical complement pathway, has been shown to
bind to apoptotic cells and enhance their clearance by inducing the activation of the
complement pathway[27]. Our goal is to characterize the interaction between apoptotic
cells and C1q, and to quantitatively measure C1q binding to the apoptotic cells. C1q was
incubated for 30 minutes at 4⁰C after staining the cells with DAPI stain and then fixing
the cells with 4% formaldehyde. C1q was visualized by using primary and secondary
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antibodies. Images were acquired using confocal microscopy. Condensed apoptotic
nuclei were visualized using DAPI nuclear stain, a commonly used assay to assess
nuclear morphology[70]. Annexin V was not used to check for apoptosis due to its
binding affinity to PS, which can compete for C1q binding. Area of each nucleus was
obtained using the threshold tool in ImageJ to highlight the nucleus. The average from 3
days was used. The membrane of each individual cell was highlighted, and then the
intensity of C1q was obtained using ImageJ and the (Eqn. 3) listed above.

Figure 26. C1q binds to fixed apoptotic MES-SA cells.
The integrated intensity of C1q binding reflects the mean ± SE of three experiments. N=
47, 53, 44 cells for non-treated cells, cells treated with DMSO, and valinomycin
respectively. The intensity of the background for each image was subtracted. Statistical
significance was observed (P=0.022) between the average area of nuclei of cells treated
with DMSO, and apoptotic cells. The average area of nuclei of cells treated with neither
DMSO nor valinomycin was significantly less than average area of apoptotic cells
(P=0.008). No statistical significance was observed of the average C1q intensity between
control and apoptotic cells.
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Cells treated with valinomycin are shown to decrease in the area of the nuclei as
compared to the cells exposed to DMSO or cells treated with neither valinomycin nor
DMSO. The average area of apoptotic cells’ nuclei, DMSO treated cells ‘nuclei, or the
nuclei of cells not exposed to DMSO or valinomycin are 83.60±4.30, 112.44 ±5.28, and
128.46 ±7.98 respectively. The fluorescence integrated intensity of C1q increases when
cells were apoptotic.
Quantitatively, the average intensity of C1q bound to apoptotic cells is 114497.80
± 14516.46 whereas the cells treated with DMSO have less C1q bound to them as
reflected by the fluorescence average intensity which is 95986.25 ± 11497.00. Untreated
cells have less C1q bound to them with an average fluorescence intensity 77747.39 ±
1211.79.

3.3. Aptamer binds to apoptotic cells incubated with pCRP and mCRP over time
pCRP loses its pentameric structure and undergoes conformational rearrangement
when it binds to endothelial cell membrane, forming mCRP that deposits in the blood
vessel walls[23]. Our lab recently identified a RNA aptamer that binds specifically to
mCRP but not pCRP[42]. In this research, aptamer was utilized to investigate whether the
membrane of apoptotic cells can induce CRP conformational change. To follow the
conversion from pentameric to monomeric form, CRP was incubated with the MES-SA
apoptotic cells with different incubation time. The average intensity of aptamer binding
to the membrane of apoptotic cells was determined by using ImageJ. The membrane of
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each individual cell was highlighted, then the intensity of aptamer was calculated by
using this equation:
𝐴𝑝𝑡𝑎𝑚𝑒𝑟 𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 = 𝐴𝑝𝑡𝑎𝑚𝑒𝑟 𝐼𝑛𝑡𝑒𝑔𝑟𝑎𝑡𝑒𝑑 𝐷𝑒𝑛𝑠𝑖𝑡𝑦 𝑜𝑓 𝐶𝑒𝑙𝑙 𝐴𝑟𝑒𝑎 −
(𝑀𝑒𝑎𝑛 𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑 𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 × 𝐶𝑒𝑙𝑙 𝐴𝑟𝑒𝑎)
Equation 6

The results show high aptamer binding intensity with the cells incubated with mCRP,
while the cells incubated with pCRP show less binding (Table 1). Also, the results
indicate higher intensity of aptamer binding to the cells incubated for two hours with
pCRP as compared to the cells incubated for one hour.
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A)

B)

Figure continues on the next page.
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C)

Figure 27. Aptamer binds to apoptotic cells at different time incubation.
A) Aptamer binds to apoptotic cells after incubating with mCRP for 2h, B) pCRP for 2h.
C) Average integrated density of aptamer binds to apoptoic cells at varying incubation
time with the antibody background intensity subtracted. Error bar is SEM. N=248,337
and 281, 364 for pCRP and mCRP at 2hrs, 1hr respectively. Statistical significance was
observed (p<0.0001) between pCRP, mCRP treated cells.

3.4 Discussion
Due to the significant role of CRP and C1q in removing apoptotic cells and
activating the complement system pathway, we aimed to quantitatively assess the binding
of these proteins to apoptotic cells. The results revealed that CRP preferred to bind to
apoptotic cells compared to control cells. Previous studies have confirmed colocalization
of CRP on the apoptotic cell surface[19].
We also investigated whether the membrane of apoptotic cells induce pCRP
structural changes to mCRP. A RNA aptamer that specifically binds to mCRP but not to
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pCRP was utilized in this study to follow the pCRP conversion to mCRP on the surface
of apoptotic cells membranes. The average intensity of aptamer that bound to cells
incubated with mCRP was significantly higher (p<0.0001) than cells incubated with
pCRP for two hours and one hour. Also, cells incubated with pCRP for two hours have
showed significant aptamer binding than cells incubated with pCRP for one hour
(p<0.0001). These data indicate that during two hours of incubation, more pCRP
molecules dissociate to mCRP upon binding to the membrane of the apoptotic cells. Our
finding is in agreement with previous work that showed the rapid dissociation of pCRP
on the surface of apoptotic Jurkat T cells after 30 minutes of incubation by using mCRP
mAB 3H12[19].
To further confirm our finding, future work can measure tryptophan fluorescence
of CRP after varied incubation time with apoptotic cells by using the supernatant to
detect conversion of pCRP to mCRP. However, separation would be extremely
challenging. Due to CVD relevance, future work can focus on using Human Aortic
Endothelial Cells (HAEC) to investigate if conditions for pCRP conversion is cell type
specific or universal. Since previous studies suggested that binding pCRP to apoptotic
cells is mediated by lysoPC[56], fluorescently tagged lysoPC and CRP can be used for
colocalization analysis for imaging.
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CHAPTER FOUR
4.1 Using fluorescence binding assays to characterize CRP conformational changes
4.1.1 Protein denaturation
Proteins in their native states have three dimensional folding structures known as
secondary, tertiary, and quaternary structure. The proper function of a protein relies on its
native form. Exposing a protein to any factor such as organic solvents, acids, bases and
heat leads to the protein losing its native form and ability to perform its biological
activity, and to protein denaturation. On the cellular level, denaturation of a protein
causes disruption in the biological activity and cell death. Denaturation of proteins causes
major changes in original native form of proteins without altering their primary
structures. It is well-known that the structure of a protein dictates its function.
Urea is a well-known denaturant shown to destabilize the native structure of a
protein. Two mechanisms have been proposed to interpret the denaturation effect of urea,
a direct and an indirect mechanism. Direct mechanism is when urea interacts with
hydrophobic side chains, polar side chains or with the backbone. Indirect mechanism is
when urea changes the water properties to a solvent which causes protein denaturation. It
has been shown that van- der Waals interactions between the hydrophobic solute and
solvent is more attractive in urea due to an enthalpic driving force[71],[72]. This is
explained by the large dipole moments and the high polarizability of urea. Calorimetric
studies revealed that adding a high concentration of urea, up to 2M, to globular proteins
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decreases the enthalpic and the entropy of unfolded proteins, which in turn decreases the
Gibbs free energy of unfolding proteins and promotes protein unfolding[73].
Guanidine-HCl is a widely used denaturant that destabilizes the native states of
macromolecules. It is a chaotropic agent that disrupts a non-covalent forces such as
Vander Waals interaction, hydrogen bonding and hydrophobic effects.
Experimental contributions from Carrie Moon in this chapter include gel electrophoresis,
tryptophan fluorescence, and ELISA.

4.1.2 Fluorescence binding assay of 8-anilino-1-naphthalenesulfonic acid (ANS)
To monitor CRP unfolding after incubation with different denaturants, 1Anilinonaphthalene-8-sulfonic Acid (ANS), a hydrophobic fluorescent probe was
utilized. ANS has been used frequently in biochemistry and biophysics research to study
protein folding and aggregation. ANS has polarity due to its negative charge on the
sulphonated naphthalene group and due to the amide group electrons in the aniline ring
that form hydrogen bonds with the proteins.
It also has hydrophobicity due to its aniline ring and
naphthalene backbone. ANS aromatic rings help to
stabilize its binding with apolar regions of
proteins[74].
ANS binds to hydrophobic regions of protein
noncovalently which leads to significant increase in
quantum yield. The orientation of the two naphthyl groups
of ANS becomes oriented in parallel upon binding to the
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Figure 28. 1Anilinonaphthalene-8sulfonic Acid structure.

hydrophobic domains of the protein; this causes a significant increase in ANS
intensity[75]. When the protein exposes more of its hydrophobic region, the binding
events with ANS increase, which in turn causes an increase in the fluorescence intensity
accompanied by blue shift. If the protein is fully denaturated, the ANS binding will
become unstable and easily detach and become free in solution. Due to the loss of the
organized structure of the fully denatured proteins, there is no longer a complimentary
structure between the hydrophobic region and charged region, so ANS can just form one
kind of interaction with the protein. In this case, the fluorescence intensity of ANS will
become low as compared to partially denaturated proteins[74]. Possible fluorescence

Fluorescence intensity

spectra of ANS is shown in

Wavelength (nm)
Figure 29. Possible ANS fluorescence spectra.
Possible ANS spectra upon its binding to protein’s regions with different degree of
hydrophobicity.
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4.1.3 Tryptophan fluorescence assay
Tryptophan fluorescence is a widely used assay to monitor conformational
changes of proteins. The maximum emission wavelength and the fluorescence intensity
of tryptophan (Trp) are sensitive to the polarity of its local environment which makes it a
good indicator for structural changes of proteins[76]. Trp fluorescence decreases and
shifts to red with a longer wavelength when the Trp residue is exposed to an aqueous
environment. pCRP contains 30 residues of Trp. The TRP residue location are 67, 100,
110, 162, 188, and 205 as shown in Figure 30. Inter subunit involves the 115-123 loop of
one subunit and the 40-42 and 197-202 of adjacent protomer[7].
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Figure 30. CRP amino acid sequence.
Tryptophans are found as residues 67, 100, 110, 162, 188, and 205.Image was taken from
the protein data bank (PDB Identifier: 1B09).
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4.2 Material and Methods
4.2.1 Modified Native PAGE
CRP forms were visualized using a modified Native Polyacrylamide Gel
Electrophoresis system (PAGE)[42]. Standard Laemmli conditions were followed with
the exception of using 0.005% SDS in the gel and using a native loading buffer (no SDS,
BME, or heat). 0.43 μg of CRP was loaded in each well. Gels were run at 80 V for 2
hours and then silver stained. Bio-RAD precision plus protein standards ladder was used.

4.2.2 Tryptophan Fluorescence
Tryptophan Fluorescence of CRP was read using a Tecan Infinite M1000 plate
reader with samples in Corning black half-area 96 well plates (product #3694).
Measurements were made with an excitation wavelength of 280nm. The integral from the
emission spectra from 300-400nm was used for comparing fluorescence intensity, and
then each value was normalized to the average pCRP integrated intensity.
The standard buffer used in the experiments was 30 mM HEPES, 2 mM CaCl2,
140 mM NaCl (chemicals purchased from Thermo-Fisher or Sigma Life Sciences unless
otherwise noted). Purified human CRP (Academy Bio-medical Company #30P-CRP110)
was used as pCRP when diluted with the standard buffer. CRP concentration per sample
was 57.5 μg/mL. Each denaturant used for converting pCRP to mCRP was made in the
standard buffer mentioned above. Stock solutions of 8 M urea, 10 mM EDTA and 6 M
guanidine hydrochloride were made in the standard buffer and used for dilutions. Urea
and guanidine CRP conversion trials were allowed to incubate for 2 hours at room
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temperature prior to analysis. mCRP was also made with 0.01% SDS in standard buffer
and heated for 1 hour at 80-85°C[42].

4.2.3 Binding assay of 1-Anilinonaphthalene-8-sulfonic Acid (ANS)
ANS, a hydrophobic fluorescent probe (Cayman chemical) was used to monitor
the conformational changes of CRP after treating the protein with different denaturants.
The stock solution of ANS was made using dimethyl sulfoxide (DMSO), and diluted to a
final concentration of 200 μM by using Millipore water. Guanidine hydrochloride (2.5M,
5.7M), Urea-EDTA (3M, 6M) and HEPES buffer containing 2 mM CaCl2, 140 mM NaCl
with pH value 6.4 was used. CRP (50μg/ml) was incubated with the denaturants for 2
hours at 37°C.Then, ANS was added to the black polystyrol half area 96 well plate (Life
Science). The fluorescence intensity of ANS was measured in a spectrofluorometer
(Infinity M1000) by using an excitation wavelength of 390 nm, and an emission
wavelength from 440 nm to 650nm. Tryptophan fluorescence measurements were also
done before and after adding ANS to the plate.

4.3.3 Enzyme Linked Immunosorbent Assay (ELISA)
The binding of CRP to C1q was measured by performing an ELISA with C1q as a
capture at a concentration of 1 µg/mL, following previously published procedures[42].
Bovine serum albumin (BSA, 1 µg/mL) was used as a control in place of the C1q
capture. BSA and C1q were diluted in coating buffer (30 mM sodium carbonate, 70 mM
sodium bicarbonate, pH 9.6, Sigma Aldrich). 100 µL of coating solution was added to the
microwells in a Microlon 600 96W high binding clear microplate (Greiner Bioscience
80

655081). After a 2 hour incubation at 37 °C, wells were washed three times with 300 µL
of phosphate buffered saline with 0.05% Tween-20 (PBST; Acros Organics) and once
with 300 µL of phosphate buffered saline (PBS, pH 7.4). This was followed by tapping
the plate dry on a stack of paper towels and Kimwipes. Next, 300 µL of blocking buffer
(3% w/v BSA in PBST) was added and the plate was incubated at room temperature for 2
hours. In between each step in the assay, wells were washed as described above (300 µL
in each well, 3 times with PBST and once with PBS) and then tapped dry on paper
towels. 100 µL of CRP (1.8 µg/mL) in diluting buffer (1% w/v BSA in PBS) was added
and incubated for 1 hour at 37 °C. The primary antibody, a biotinylated polyclonal antiCRP was diluted at a ratio of 1:5,000 in diluting buffer and 100 µL was added and
incubated for 1 hour at 37 °C. After washing, 100 µL of a 1:10,000 dilution of
streptavidin-HRP (FROM?) was added to each well and incubated for 30 minutes at 37
°C. A final wash sequence was followed by the addition of 100 µL of 3, 3’, 5, 5’tetramethylbenzidine (TMB) substrate. After the color was allowed to develop (5-10 min)
at room temperature, the reaction was stopped by the addition of 100 µL of 0.5 M
sulfuric acid, turning the reaction solution from blue to yellow. Absorbance was
measured at 450 nm, with a reference absorbance of 620 nm on a Microplate reader
(Tecan infinite-M1000 PRO) plate reader.
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4.3 Results and Discussion
4.3.1 Denaturing CRP reveals metastable states
To determine the stability of the native, pentameric form of CRP, we denatured
CRP using two common denaturants, Urea with EDTA and GndHCl. The intrinsic,
tryptophan fluorescence was measured and decreased with increasing denaturant, as
expected, for most concentrations (Figure 31A and B). The change in fluorescence occurs
as some of the 6 Trp residues (per monomer of CRP) go from a hydrophobic, protein
environment to a more aqueous environment, where the fluorescence is substantially less.
Denaturation with GndHCl led to a clear transition (Figure 31A) between 2.0 and 2.5 M
GndHCl, however, the gradual decline in fluorescence from 0 to 2 M suggests
conformational changes are occurring even at low concentration. CRP denatures quite
easily but does not denature fully, as determine by comparing the fluorescence at 5M
GndHCl to that of free Trp of the same concentration (Figure 30A).
After measuring the intrinsic fluorescence to identify changes in the exposure of
Trp residues to aqueous environment, samples were loaded onto a native gel to assess the
presence of different states of CRP. In Figure 31C, D, a clear transition occurs where a
modified form of CRP begins to show up, running similar to the 20 kDa standard. pCRP
is a 110 kDa pentamer with a pI at 6.4 and the pI changes to 5.6 upon
monomerization[10]; both the molecular mass and the charge affect migration in this
assay. The pentameric form is less charged and larger and therefore does not run well
into the gel. With GndHCl treatment, this band first shows up at 1.75M GndHCl and is
fully present at 2.75M, matching the profile of intrinsic fluorescence in Figure 30A.
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Figure 31. Intrinsic fluorescence and native PAGE assays of CRP treated with GndHCl
and Urea.
Intrinsic, tryptophan fluorescence was measured by exciting solutions at 280 nm and
recording fluorescence from 300-400 nm. The integrated fluorescence was normalized by
the 0 M denaturant data point. Fluorescence decreased with increasing denaturants for
both GndHCl (A) and Urea with EDTA (B). The dashed line in both represents the
fluorescence intensity observed from an equivalent amount of free Trp. Error bars are
+/- SEM. C) Native PAGE of GndHCl treated CRP with two hours of incubation, D)
Native PAGE of Urea:EDTA treated CRP with two hours of incubation.

When pCRP is treated with Urea and EDTA, a clear transition exists in the gel
from 2.25 to 4.0 M urea. The mCRP band increases over this range and the pCRP (not
shown but retained in the stacking portion of the gel) disappears. A haze of protein is also
observed in the gel and this fully disappears at 4.0M. This could be alternative states of
pCRP that have not been fully characterized and these are present in the absence of Urea
(Figure 31 D, 0M). The transition likely occurs over a larger range of urea concentrations
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because urea is a weaker denaturant than GndHCl. Interestingly, the observed transition
with Trp fluorescence is gradual from 2 – 6 M urea, over a much wider range than that
observed in the gel, suggesting that conformational changes are still occurring that affect
the Trp environment, but these changes do no broadly influence the size or charge of the
protein in a way that affects how it runs on a gel.

4.3.2 Hydrophobic portions of CRP are exposed
To monitor CRP unfolding after incubation with different denaturants, 1Anilinonaphthalene-8-sulfonic Acid (ANS), a hydrophobic fluorescent probe was
utilized. ANS is used frequently in biochemistry and biophysics research to study protein
folding and aggregation. ANS binds to hydrophobic regions of proteins, which leads to a
significant increase in quantum yield and a blue shift in the emission maxima[74], [77].
As shown in Figure 32, treatment with 2.5M GndHCl (Figure 31A), 3 or 6 M urea (
Figure 32B), or 0.01% SDS Figure 32C caused hydrophobic portions of CRP to be
exposed. SDS-treated CRP showed the biggest change Figure 32 C, black circles from
the untreated CRP (solid line in all figures). This means that more hydrophobic regions
were exposed to ANS, and we suggested that this modified form of CRP (mCRP) mimics
the physiological form of mCRP and maintain CRP function with downstream bindingTB
partners as shown by another experiments performed in our lab.
Our data revealed an increase in ANS fluorescence intensity with a high degree of
blue shift when CRP was treated with 2.5M of GndHCl or 3M of Urea-EDTA. This could
be due to an increase in the degree of hydrophobicity which leads to a strong binding
between ANS and CRP. However, a high concentration of the denaturants, 3M of
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GndHCl and 6M of Urea-EDTA caused a decrease in ANS fluorescence intensity with
low degree of blue shift Figure 32. At high concentration of GndHCl, ANS still retains
high fluorescence. If a protein is completely unfolded, ANS does not bind. This agrees
with Figure Figure 31A where Trp fluorescence remains despite high concentrations of
GndHCl. Both demonstrate that CRP retains structure in high concentration of
denaturant. CRP exposed to BME and heat showed less binding to ANS and less degree
in blue shift Figure 32C as compared with CRP that treated with SDS. This reduce in
ANS fluorescence could be attributed to the reducing effect of BME which disrupts the
disulfide bond in the protein and leads to protein aggregation.

Figure 32. Treatment of pCRP with denaturants increase binding of 1Anilinonaphthalene-8-sulphonic acid (ANS).
A) ANS fluorescence upon binding to pCRP incubated with 2.5 M GndHCl (filled
circles) or 3.0 M GndHCl (open circles) for 2 hours at 37°C. B) ANS fluorescence upon
binding to pCRP incubated with 3 M (open circles) and 6 M (filled circles) Urea-EDTA
at 37°C for 2 hours. C) ANS fluorescence upon binding to pCRP that was incubated with
0.01% SDS and BME then heated at 100°C for one hour (open circles) or 0.01% SDS
then heated at 80°C for one hour (filled circles). In all figures, ANS fluorescence when
bound to pCRP without treatment is shown as a solid line.
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4.4.4 SDS induced changes specifically increase C1q binding
In our lab we compared a variety of methods for synthesizing mCRP from serum
purified pCRP, which were tested for the ability to produce a form that binds C1q, one
downstream binding partner of CRP in the complement immune response. One of the
methods for altering the conformation of pCRP is with 0.01% SDS and heat. ELISA
experiments, performed by Carrie Moon, with C1q or BSA used to capture CRP were
used to compare binding of different CRPs. A polyclonal antibody to CRP with a biotin
linkage was used to then bind horseradish peroxidase linked streptavidin (HRP-Strep). In
Error! Reference source not found., the SDS treated CRP (blue) clearly shows
significant binding to C1q as compared with pCRP (purple), or the antibody (green). The
significant difference between mCRP and pCRP was confirmed with a Student’s t-test p
value of 0.0071 (unpaired, two-tailed). pCRP binding to C1q is similar to the antibody
(green) which indicates that pCRP does not bind C1q measurably. When BSA is used as
a capture, pCRP shows no significant binding (orange) as compared with C1q captures
for pCRP (blue). BSA captures slightly more 0.01% SDS and heat treated CRP than
pCRP (pink) or antibodies (yellow), but mCRP with C1q as a capture (blue) still shows
the strongest binding. This data indicates that CRP treated with 0.01% SDS in 80°C for
an hour produces a modified form that is biologically relevant to mCRP observed in vivo
due to C1q binding. This agrees with the work of Wang et al[21], where fluorescence
anisotropy revealed that SDS treated CRP binds C1q.
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Figure 33. Dilute SDS treated CRP binds C1q in an ELISA assay.
C1q or BSA was used as a capture agent for CRP. C1q captures CRP treated with 0.01%
SDS and heated at 80°C for 1 hour (blue), but not pCRP (purple) or antibodies (green).
BSA captures CRP significantly less than C1q (orange), but captures more 0.01% SDS:
heat treated CRP than pCRP (pink) or antibodies (yellow). Error bars are +/- SEM and
significance between mCRP and pCRP with C1q capture using an unpaired, two-tailed ttest is 0.0071.
.
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4.4 Conclusion
In this work, we compared the unfolding of CRP using different chemical
denaturants. We used Urea/EDTA, guanidine HCl, and 0.01% SDS with heat to perturb
the pentameric state. All treatments give rise to a monomeric state in native PAGE
experiments, but only dilute SDS with heat treatments maintain CRP function with
downstream binding partners. Biological activity of the monomeric state was tested by a
binding assay with C1q, a downstream binding partner of mCRP. This is consistent with
what others have seen in past studies[21].
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CHAPTER FIVE: SUMMARY

In this work, CRP binding and conversion was characterized as a function of
membrane shape and chemical composition using a supported lipid bilayer biosensor that
mimics the cell membrane. Despite knowing that the modified form of CRP, mCRP,
binds downstream partners proteins better than the soluble form, pCRP, little is known
about how these conformations affects CRP membrane interactions. The design of the
biosensor permits to separately tune the lipids compositions and membrane shape. The
primary component of lipids was POPC with and without lysoPC to mimic damaged
membranes. The shape of membrane and curvature was controlled by using fluorescence
nanoparticles with diameters (45 nm, 100 nm). Using this model system combined with
quantitative fluorescence microscopy methods, CRP binding to lipid membranes was
measured as a function of different conformations of CRP. The monomeric form of CRP
bound curved membranes, but the pentameric form did not until membranes became
highly curved (radius = 27 nm). Unlike most other curvature sensing proteins, mCRP
accumulated at a higher density in lower curvatures. The presence of lysoPC increased
binding of CRP to all membranes. Overall, our results show that the protein form, lipid
composition, and membrane shape affect CRP interactions differently and the mechanism
by which CRP recognizes damaged membranes depends on the combination of all three.
CRP interactions with cellular membranes was also investigated in this work
using MES-SA cells. Valinomycin and Paclitaxel were used to induce apoptosis in MES89

SA cells. Apoptosis was confirmed using Annexin V, a protein binds to
phosphatidylserine that exposed to the outer leaflet of the plasma membrane during the
apoptosis. The data showed that CRP binds to the membrane of apoptotic cells more than
the control cells.
Disassociation of CRP on the membrane of the apoptotic cells was then monitored
by using a RNA-aptamer that binds specifically to mCRP. Cells incubated for two hours
with mCRP bound aptamer significantly more than cells incubated for an hour. CRP
incubated with apoptotic cells for two hours significantly bound aptamer more than CRP
incubated for an hour. These results suggested that during two hours of incubation more
pCRP disassociates to mCRP.
Unfolding of CRP was also characterized in this work using different chemical
denaturants. Urea/EDTA, guanidine HCl, 0.01% SDS, and heat were used to perturb the
pentameric state. All treatments give rise to a monomeric state in native PAGE
experiments. The change in conformation was also assessed by tryptophan and ANS
fluorescence. ANS binds to hydrophobic regions of proteins, which leads to a significant
increase in quantum yield and a blue shift in the emission maxima. ANS fluorescence
intensity increased when CRP treated with 2.5M Gnd-HCl, and with 3M urea-EDTA
suggested that more hydrophobic regions were exposed and bound to ANS. The effect of
different pH on CRP conformation was also assessed using ANS.
This work could lead to a more specific diagnostic test for CVD risk based on
CRP conformers and provide a new direction for atherosclerosis treatment.
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APPENDIX
Supplemental Figures

S 1. Native PAGE of pCRP, mCRP in HEPES, and PIPES buffer.
a- Ladder. b,c- 50ug/ml of pCRP in HEPES, and PIPES respectively. d,e40ug/ml of pCRP in HEPES, and PIPES respectively. f- 30ug/ml of pCRP in
PIPES. g,i- mCRP made by heating pCRP with 0.01%SDS at 80c for an hour
and left overnight before loaded to gel. h, and j- fresh mCRP.

S 2. Dot blot of primary anti- C-reactive protein (C6), mouse IgG monoclonalantibody, and secondary goat anti mouse immunoglobulin G with Alexa 488.

100

S 3. Dot blot of primary anti- C-reactive protein (D7), mouse IgG monoclonal-antibody,
and secondary goat anti mouse immunoglobulin G with Alexa 488.This has been done
twice and it is qualitatively the same with mCRP less intense than pCRP.

Disassociation constant for the interaction of CRP with different ligands as determined
by surface plasmon resonance
Kd
CRP-Phosphorylcholine

18 µM

pCRP-pCRP

23 µM

pCRP-C1q

1.45 nM

mCRP-C1q

0.28 nM
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Matlab Codes used for these experiments
CALCCORF CODE by Dr. Michelle Knowles
function out=calccorf (red, green)
% CALL: out=calccorf(red, green);
%
% PURPOSE: to measure the Pearson's correlation coefficient between pairs of cropped
images.
% INPUT:
% red: a ministack of croppped images that are stable in time (red NPs,
% granules, clathrin pits, etc)
% green: a ministack of cropped images that are more variable (syx,
% proteins) - this is the channel that intensity is measured for.
nredrows = length(red(1,1,:));
ngrnrows = length(green(1,1,:));
nrows = min(nredrows, ngrnrows);
msk = zeros([1,2]);
for i = 1:nrows;
g = green(:,:,i);
r = red(:,:,i);
normg = double(g)/double(max(max(g)));
normr = double(r)/double(max(max(r)));
% calculate the Pearson's correlation coefficent (code from Taraska).
msk (i,1) = corr2(normr, normg);
% remove saturated images DOES NOT WORK
% if max(max(g)) OR max(max(r)) = 4095 then
%
msk (i, 2) = NaN
msk (i,2) = corr2(normg, normr);
end
mean(msk)
out = msk;
end
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RUN_MINISTK CODE modified by Mitch Alton
function [] = run_ministk ( )
%ask for red and green channels
[redfile,redpth] = uigetfile('*.tif','Select the Red Channel');
[grnfile,grnpth] = uigetfile('*.tif','Select the Green Channel');
%ask where to save the resulting file
[savefile,savepth] = uiputfile('*.mat','Where to save the Results');
%read in an image
a=imread([redpth,redfile]);
c=imread([grnpth,grnfile]);
%view the image, imagesc autoscales.
colormap('gray'),imagesc(a);
% filter the image, 9 is a size, filter things larger than 9 pixels, and filter 1 or smaller
b=bpass(a, 1, 9);
colormap('gray'),imagesc(b);
colormap('gray'),image(b);
%seems to make a saturated mask like image when using beads
%use the filtered image to find regions. 1500 is the threshold and 9 is a size of feature
%you are looking for. Should be the same as above. RECORD THESE NUMBERS IN
%YOUR NOTEBOOK!
pk=pkfnd(b, 100, 9);
%find centroids - NOT NEEDED for colocalization routine
cnt=cntrd(b, pk, 15);
%overlay regions onto non-filtered image. Adjust the threshold to find fewer or more
%spots.
colormap('gray'),imagesc(a);
hold on
plot(pk(:,1), pk(:,2), 'ro');
zoom
%once you like the threshold and want to cut out ministacks
%do this with both color channels so that you can check it.
cutout_red = ministk(a, pk, 24, 9);
cutout_grn = ministk(c, pk, 24, 9);
%a is the image you will be cropping, pk are the regions you would like to crop, 24 (+1)
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%is the size of images you will cut out and if spots are too close (within 9 pixels of one
%another) you will not count either of them.
%save the file
stkwrite(cutout_red,strcat(savefile,'-red.stk'),savepth);
stkwrite(cutout_grn,strcat(savefile,'-grn.stk'),savepth);
cutout_red_avg = uint16(mean(cutout_red,3));
cutout_grn_avg = uint16(mean(cutout_grn,3));
stkwrite(cutout_red_avg,strcat(savefile,'-red-avg.stk'),savepth);
stkwrite(cutout_grn_avg,strcat(savefile,'-grn-avg.stk'),savepth);
%see what regions were kept and save them. You do NOT need to do this with both
%image files, since the spot locations will be identical.
finalspt = keptspot(a, pk, 24, 9);
save(fullfile(savepth,savefile));
% you can view what spots were kept and what were ?too close? to others or the edges.
colormap('gray'),imagesc(a);
hold on
plot(finalspt(:,1), finalspt(:,2), 'ro');
zoom
%% Make a radial plot of pixel intensity
% This is Mitch Alton's implementation
hold off;
[m, n]=size(cutout_grn_avg);
%finds size of the image
x=[1:n];
l=repmat(x,n,1);
%creates matrix of repeating columns of 1 through how ever many columns
%there are in the image
y=[1:m];
y';
p=repmat(y,m,1);
w=p';
%creates matrix of repeating rows
x=l-(((n-1)*0.5)+1);
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y=w-(((n-1)*0.5)+1);
%makes matrixes -# to +#. Not sure how this will work with even numbers
%though
z=cutout_grn_avg(1:m,1:n);
%creates a matrix of intensities from image
[THETA,RHO,Z]=cart2pol(x,y,z);
%converts three matrixes to a three dimentional polar coordinate matrix
%G=reshape(z,1,625);
%H=reshape(RHO,1,625);
%turns matrix into a list of values
[t,I,J] = unique(RHO);
s = zeros(size(t));
frequencies = zeros(size(t));
for i = 1:max(J)
I = find(J==i);
s(i) = mean(Z(I));
frequencies(i) = length(I);
end
plot(t,s)
% Save the files
radialPlot = cat(2,t,s);
hgexport(gcf, fullfile(grnpth,[savefile '-grn-radial.png']), hgexport('factorystyle'),
'Format', 'png');
csvwrite(fullfile(grnpth,[savefile '-grn-radial.csv']), radialPlot);

[m, n]=size(cutout_red_avg);
%finds size of the image
x=[1:n];
l=repmat(x,n,1);
%creates matrix of repeating columns of 1 through however many columns
%there are in the image
y=[1:m];
y';
p=repmat(y,m,1);
w=p';
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%creates matrix of repeating rows
x=l-(((n-1)*0.5)+1);
y=w-(((n-1)*0.5)+1);
%makes matrixes -# to +#. Not sure how this will work with even numbers
%though
z=cutout_red_avg(1:m,1:n);
%creates a matrix of intensities from image
[THETA,RHO,Z]=cart2pol(x,y,z);
%converts three matrixes to a three dimentional polar coordinate matrix
%G=reshape(z,1,625);
%H=reshape(RHO,1,625);
%turns matrix into a list of values
[t,I,J] = unique(RHO);
s = zeros(size(t));
frequencies = zeros(size(t));
for i = 1:max(J)
I = find(J==i);
s(i) = mean(Z(I));
frequencies(i) = length(I);
end
plot(t,s)
% Save the files
radialPlot = cat(2,t,s);
hgexport(gcf, fullfile(grnpth,[savefile '-red-radial.png']), hgexport('factorystyle'),
'Format', 'png');
csvwrite(fullfile(grnpth,[savefile '-red-radial.csv']), radialPlot);
%close
end
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MINISTK CODE by Dr. Michelle Knowles

function out=ministk(im,rgn,sz,sepdist)
% out=ministk(im,rgn,sz)
%
% PURPOSE: to cut out small regions of an image based on spots found in
% the image or a corresponding image of a different color. This is used to
% measure colocalization based on the work of Knowles and Barg in two PNAS
% 2011 papers. Spots are found using the work of tracking routines
% available on Eric Weeks' website (Emory University) and made into Matlab
% by Eric Dufrense.
% INPUT:
% im: image to cut from
% rgn: spots (x,y) about which regions should be cut
% sz: size of cut out (a square of sz by sz pixels)
% sepdist: is the minimum separation distance between two spots. If two
% spots are within this distance of one another, neither are counted.
%
% OUTPUT: a sz x sz x N image array
%
% CREATED: Michelle Knowles May 2012
%if sz/2 == floor(sz/2)
%warning('sz must be even so that the spots can be centered on a pixel: 1 pixel added');
%sz = sz+1
%end
%scott's code for a mask
pix=(sz+1)/2;
dim = length(im);
nrgn = length(rgn(:,1));

%create a blank image array that you can fill
msk=zeros([sz+1,sz+1]);
%loop through all regions that locate spots in an image
for i =1:nrgn;
x = rgn(i,1);
y = rgn(i,2);
%don't include regions within pix distance from the edge of the image.
if ((x>pix) & ((x+pix)<dim) & (y>pix) & ((y+pix)<dim))
% don't include regions within "sepdist" pixels of another region
% calculate an array that contains the difference between the
% current particle's postion and all others.
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diffy=rgn(:,2)-rgn(i,2);
diffx=rgn(:,1)-rgn(i,1);
mag=((diffx.*diffx)+(diffy.*diffy).^0.5);
% find all the locations in the magnitude array that are non-zero.
% This should remove the comparison between particle i and itself,
% which will always be zero.
w = find(mag);
mag = mag(w);
if (min(mag) > sepdist)
cutout = imcrop(im,[x-pix y-pix sz sz]);
msk = cat(3, msk, cutout);
end
end
end
out=msk;
end
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COLO_NORM CODE by Mitch Alton

%better_colo plots intensities of a location guided average image as a
%function of distance from the center of the image. The second hald of the
%program finds the area under the peak of the radial intensity plot. It
%does this by dividing by the mean of the data after
%the third pixel.
%Written by Mitch Alton on 7/15/15
[m, n]=size(a);
%finds size of the image
x=[1:n];
l=repmat(x,n,1);
%creates matrix of repeating columns of 1 through however many columns
%there are in the image
y=[1:m];
y';
p=repmat(y,m,1);
w=p';
%creates matrix of repeating rows
x=l-(((n-1)*0.5)+1);
y=w-(((n-1)*0.5)+1);
%makes matrixes -# to +#. Not sure how this will work with even numbers
%though
z=a(1:m,1:n);
%creates a matrix of intensities from image
[THETA,RHO,Z]=cart2pol(x,y,z);
%converts three matrixes to a three dimentional polar coordinate matrix
G=reshape(z,1,(m*n));
H=reshape(RHO,1,(m*n));
%turns matrix into a list of values
[t,I,J] = unique(H);
s = zeros(size(t));
frequencies = zeros(size(t));
for i = 1:max(J)
I = find(J==i);
s(i) = mean(G(I));
frequencies(i) = length(I);
end
%this averages the intensities (Z) for single distance (RHO) values
ydatatemp=s(:,8:83);
%limits the yvalues to just the values past 3 pixels from the center of the
%image. The nanoparticle seems to only be 3 pixels in radius.
base=mean(ydatatemp);
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%finds the average of all of the data past the 3rd pixel for the height of
%the rectangle
yaxis=s/base;
ypeak=yaxis(:,1:7);
plot(t,yaxis)
clear sum
x=sum(ypeak);
answer=x-1
%this gives a number for the area of the peak from the colocalization
%as the answer

110

SPOTTEST CODE by Dr. Philip Cheney
%spottest -- Load, look for spots, show a picture
%
% this program is used to determine the properties of a movie or image
% containing spots.
%
% INPUT:
% movieOrImage is a movie or image containing spots
%
%
% PC 24 Apr 2014
%
% This is converted from the old spot check functions, so there may be
% unused cruft still hanging around in here.
figure;
movieOrImageLoaded = loadSingleTIFF(movieOrImage);
sawSpots = seeingSpotsAml(movieOrImageLoaded,1);
imshow(movieOrImageLoaded(:,:,1),[min(movieOrImageLoaded(:))
max(movieOrImageLoaded(:))*0.5]);
hold on;
plot(sawSpots.spotsDetected(:,1,1),sawSpots.spotsDetected(:,2,1),'ro','MarkerSize',20);
title('Frame 1');
if eq(sawSpots.isMovie,1)
figure;
sawSpots = seeingSpotsAml(movieOrImageLoaded,sawSpots.numberFrames);
imshow(movieOrImageLoaded(:,:,sawSpots.numberFrames),[min(movieOrImageLoaded
(:)) max(movieOrImageLoaded(:))*0.5]);
hold on;
plot(sawSpots.spotsDetected(:,1,1),sawSpots.spotsDetected(:,2,1),'ro','MarkerSize',20);
title(['Frame ',num2str(sawSpots.numberFrames)]);
end
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